var title_f25_33_26128="Types of pessaries";
var content_f25_33_26128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Commonly used vaginal pessaries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Smith; (B) Hodge; (C) Hodge with support; (D) Gehrung; (E) Risser; (F) Ring with diaphragm; (G) Ring; (H) Cube; (I) Shaatz; (J) Rigid Gellhorn; (K) Flexible Gellhorn; (L) Incontinence ring; (M) Inflatoball; (N) Donut.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Milex Products, Inc., Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26128=[""].join("\n");
var outline_f25_33_26128=null;
var title_f25_33_26129="Lower extremity rotational alignment";
var content_f25_33_26129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Rotational alignment of the lower extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 633px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rotational alignment of the lower extremity is determined by the position of the foot, the rotation of the tibia in relation to the transcondylar axis of the femur (tibial torsion), and the rotation of the neck of the femur in relation to the transcondylar axis of the femur (femoral anteversion).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26129=[""].join("\n");
var outline_f25_33_26129=null;
var title_f25_33_26130="DISH CT cervical spine";
var content_f25_33_26130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ossification of posterior longitudinal spinal ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 521px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This reformatted multislice CT scan shows ossification of the posterior longitudinal spinal ligament in a patient with diffuse idiopathic skeletal hyperostosis (DISH).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neal Roberts, MD and Curtis Hayes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26130=[""].join("\n");
var outline_f25_33_26130=null;
var title_f25_33_26131="Face holoprosencephaly";
var content_f25_33_26131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    At 19 postmenstrual weeks, this fetus with trisomy 13 and alobar holoprosencephaly also displays abnormal facies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The orbits are very close together (hypotelorism).",
"    <br>",
"     (B) There is disruption of the hard palate consistent with a midline cleft lip and palate (arrow).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Ana Monteagudo, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26131=[""].join("\n");
var outline_f25_33_26131=null;
var title_f25_33_26132="Decitabine: Patient drug information";
var content_f25_33_26132=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Decitabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     see \"Decitabine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2930134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dacogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some types of leukemias and bone marrow problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692067",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sickle cell anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701898",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to decitabine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697767",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust 1 month before care begins, during care, and for at least 1 month after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use 2 kinds of birth control that you can trust 1 month before care begins, during care, and for at least 2 months after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11480 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26132=[""].join("\n");
var outline_f25_33_26132=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930134\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021262\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021261\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021266\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021267\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021269\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021264\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021271\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=related_link\">",
"      Decitabine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_33_26133="Temporal artery biopsy technique";
var content_f25_33_26133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Temporal artery biopsy technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incision is made overlying the temporal artery. The dissection is carried through the subcutaneous fat parallel to the vessel with care not to injure the vessel, and a self-retaining retractor placed. Dividing the overlying temporoparietal fascia exposes the superficial temporal artery. The vessel is ligated proximally and distally, and the intervening segment removed. Hemostasis is achieved using electrocautery or additional sutures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26133=[""].join("\n");
var outline_f25_33_26133=null;
var title_f25_33_26134="Mastocytoma solitary";
var content_f25_33_26134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80221%7EDERM%2F50284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80221%7EDERM%2F50284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solitary mastocytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solitary mastocytoma presents as a pink-yellowish plaque that typically urticates and becomes erythematous after rubbing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Kate P&uuml;ttgen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solitary cutaneous mastocytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFDAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzu1tiVEhbgD5ufu1oQW/yjbjb61NZwerhf9r0+lWQka4KnLH261yXPbtYpNArBSq8A8+9WGjyQAMcYAxUwiYkEHp3PangMh2ock+vapbsy0ii9q3GSMDtUiQk/LtKjGBirZg2ttyWI6jsKuQ26ssfnNgk5A7gVL1E1YzmR4gsYI2dyOfzqOWIEjJO0nIFa19GA7qrKF7EY5rPVSkhD/f28D1pDgUpE+YKPmAz+NSqDtCqoyTgYqyY9qKrqAxGRxyO+c96WKEL8o5zgg0Gq2II4neUALu29R605U3qATyT69KuJC0aBsfMeMg8j8KVYguXTnAwD3oBq5UdVy4Ql1OOfemMm+YrgFQfXtVwR4jYLyDx05HvUTx4cRjDNnBINK5a7DVSJnCqcqp5+XBqwi72VQ+w/dAPUCiBUDfPwinOT3qY25YtKBhWyyg+nai+gEYt/LlJyGfHAH86ikLLtQFizjJwathGJVXOARkgHkD0pzQLkPJyy8BR1JoTGipLFJH8rEAjAwvBJpyqPNZU44BbuM+tWvKWSUyyscA5ZcE4+hNJIhaWSSQIGYksBwMe1Q9xpFaZOR5aqGJ4K96ktEXewBG7oSKl2umGQOqsuAccn/61WLa2KXBjZQsh4Bx0+tBdrIW3t1Us2QVXgfSrj2pRVVkPzLkKpz+J9KdJCgi2q6jHfHU1MiS+bMqsdpXLc8Y/GlexAx7YBV2najL0JLE/WljA3bIvlOCpbpzV+Hy9jIo52As2eRUcSEPtUDYQcO3GeeuKkqLvoQfZ1RMnaGYYPA45/WlmjZEVQ6qFGeOQauKqsu9+cAjJOD+ApJICioVVAW5DZzQV1sUoI/MkPmFxjj6mr5t5MIzqpbblStScIQXRX75OcN7GrgZ3VEO1mIJ4ONooCU+hXdQyB2VQAMdev0FOth5jYkK7RggKoA/KmDy4HwFaR/8AbB2rn0q4sCqm9SoI5LZxQZsjaJXuDIIwOc4J7fSrCBZJXGwCJO4G0Z+tJNBEXWTbnI6hiDz7d6miC+ZInPoN5x+lBDITbI5/cvu55DYHP5VK0Qhj/dAuTyRngGneYqYVkQHpx3/KmruQ7Ub5M85UE4+tBKuxktv5h3IwXaNoU8gflUd1agbdikgdccD2q7ECM8MyscHHT8KbNHvf5pFXBHyjg/QUgtZlGCMRo6q4Vm+X0/lQIVBJYsqZzgAkk+tWXZHiKOM8hf8AWEZ5ph2CJQrYAOAP7vPqB/Ogd7iqPNKq2GXOBkYallh8tfKik2YAB3ORnmpNpZdvm7FbjPb88UKjuh8qVGfOAcDOfSgT1IJYVdVbehkXkjli34elNS1DSqrSwAZxx8v4kVYNwySFZowrJklto7+5qwQhiSeOIyNglxwceh4zkUyGmQyWapGZVkj2RElBHkM3Qcj/AD0qud8UAYIjnk48rjHfn+tXoJS0RLseWG0A/dOfelvLUKgcFim44cjkH1z0xVx2FtuULVEuiiyM6xjkGM9PqCecUojcB0+3NtY5VDn8sdjRLArykJtkWI912sQfQjg1ORELdCqyLvbdlx8o/EdDQtR8qS0LE0Ye1QK8beUNzsjBmB9CCOapwQQIn71kdWJO9BzmtGGeznjMctuyXAGC4O3t65we1V5rNoZkIGCcZkAIHHrninfW5ktNyKa1YwxeRleShYH5unXP5VGltJbhxJI0ZCjIxkgevNWYzIGkaZvlyQpjGMk9z61FfPLGVkkn3lx8/UY9M0PUSiyGCRtxjRQYyoyMHB+npT7eeRBtzyvACnGPwogWMz5idYwygFW6Z+tTFA0wJClDwcDpWZaWlmeNxR7lx8oTrkAmrEEQbczPwfQcU4Bo0yR7KfSrCQySbRGN4xnHcV08zHYWKNTIqux3H0HelaNV81iQqrheR1PtTVXYBgPndjHpVvy1Yr8r5znpxUglYz40bLEp8uec1PLI3nBtq4I4HcAd6sSRkuxQ7eP4ucVB5RduTu7DPXFBooqRDJ+9ciM4RRjJ7+tCwlnxHnIH3jzgVYZA3ygfIfQcGpEZreNvL4yMbv8ACgOWxUkjWNl4MjHux6ChScFyB8xJJ/pVmJAY9xbLYwc9TThG75K7dqDPC5qXLUcU7FNQ7SgGPAOD06VaMaMf3YCg9ycY+vemqxYNuHJJ3fQdBShkALbC+9eOOhpczHYgDRs5JYoi889T7ComiULgYBLFiR6GnkmOHyyqhicksMnNMkgZpcgq38OegpMtE9tsd4o3YNGG/IVLaOXu0ZFBPIVT0FR2VqNy7DnPLE8D8Klhg2wth/bcO/8AhVdBvRiwIscczL87N8g47+tSrHkrHKvzYyBnj8+1SIRGsYnAwOcnv6Ukjs8JAYl2PTHGKm4CNCRCnzqWyc5PTFOW2LSoT85IJKmnqgVdroSBzyck1ajId1d2xKPX+lFwT5SvBBuDHOHHGW7Y9Kmih+RmEhZu5XksPWpZ0ZVLMqiTGMqOSfrUZiZtoGQU5CL/AFouilJsmt7cpEJWG5mOMfTvVuNR5bIzBpScr8uMemfWm+U32cNuORwAe5//AFVMB5IYEbnwCWDelSyCSG1VnUvIUTHJcd/cfhUrBWVEAUMQcbuijPX+tAV9qtLliVJIzjFDujEKQrEEnOMYHTNISdmRqjGRpRtZmONyjr79KVYx54j3OoX7zEcg96tMzKI0RuQOeOmfSqO4YkSEAFjwc8H1NBcU29CT/WLIUEhjU4+Y8gDpSxbnVnDqoY4BwOntUKpM0OWfbEWwHDAZI7VLGpVWCpkEjJYcgZ7Ui3EtxKoDKjkvknO4HcfenDarAeWDjjIPP4ilCRxxncVBHUnnmlRl3PtTbnBJduv+NBmSApIqs4G/oR34qXjco2gjru6ZzVfaqMxUc9RkYx9KeqyyFgpdVGDuI4FK4h8m0yLuPzDoCOPzFQO0gywTILZ49Ox61O2EXacOoOd2ckUzCqjZIB7AjOaoESOSWTkc4JA5/nTTCyhtrHeTnKnbxUgXhCCPMzgD1FTFCsjKQMY+4D1P5elAmQO/GAFHI+98xI/KpQse/hZDEDuGMEk+h9abOj5+XgLxkDP40Kiu27fuJ+XeDjP68UhaMXyUKuFX9cYHWmSIZE2I6nno2fl/A1II8EBnPC4KA7+asRwQyFdwdnYDaYxwR0570BsUJFMkaZETEdQCOR70lpCsBTdEYjnAZGzkVIYWSd1aKORmOAHAwPfmrEUCiKJCAik/LxyOO9MmegGNjJIQWA29VbIHPUY/rRcRRR24eNSSnDIScnvn0qct9mUBwJFGCWHGfXAzTZo1lcNKr+UTnoCVz0yDVJ2RF+5WhkhEMkqSBJGAUqD835EfpTDvuWJl2uVGCq8Hp3FWWt4xKq7leDPTAA/WlvIy5VreCIP6pwygfzqQuuhWXyIpQ7M0hzjB6ge3pV37ZcTjyfM+c4Ox2HIHpjqcVThV/vKwYcgcDI9QTSSFJHxJFIAANwV8EDsfYdOlWpJIUo82pcW1TcYg2yVwDt6jPoR+FZt2JJCpmKsytjr2HQf/AF60Wh2qH3iTjgEEMTTDBK8XnhUO7ja2BUydxbamZHHlWjuAFfB2hR+h9anil8oqTlXdfmBPFWZI0uWVkb94vDK/BH+Iqt5RLvHc4GzkMuSGpFbnm0MfnHZIwX5txAGenapkRnHl5IUdMDpTIj50gAXZn064q6h3QttJCL1b1rcCDyGjlHlyA7h1607y5T99ioHQirSRqApjbbk/PlecU+YvgCFQVUct3NMLFLG2PMg5+6D1JqAwumGBA3MVBHWtB2MrIWAEYB6D0pqqGYycgck7h0qW7GiTSIIomUMuOMfe7GmPHJv2gcAckVoRkso6bOACDUcqSSSMzEKpHUUtWieZma8ZeEHg5/pTkAijEe/3JHGfapDH50hwpUKBx03nv+FWba1hyS7Ku0FgeoI6VJqV9oJBwgDcfr1qPaHlUMxVFzgAY71a2qPNkfGP4SRgflTwiSjOBtU/eB70AVABNLJI4QKoJCjozDsTTBGPLd2Ckjpn+HPGBVxbfPnydVL7VIpLoIAkaKTyWLAd6BcxXg2BWVpSwySR0wPSrQOxY441OxvmYgjjNRI6p2BkbheOAPapY1bzAzgYI454A96q5Qn2dZJYwqbgehyKsm3DAN0APygVNBG0jF3XLAYAH9KeIGKsqkFMHhR/9ekTzFcxv5ZJBOT8uOmaeE5ZQmNjluv9K0GjCBH+UqADt7020tfnMjuhyCST256VnJahe5VIJSIgDd1+Y9vapjaOJPkbMnBJyOasiPzHJG0k+2Ao60+NWMpdjtyBt5z3osF7EcUEjSuXyMAkHP8ASmxKyohBBOzBCjFSyDe8rYIY5BIPXtipI0AMalMSEYAHQfWgEyURcsMN0+VSep96S9+ZyfLzGp3YXjIA5qSIAXO5yoLYIZh0PtUNzcAwsXkAXO1lJ3E8+1AQV2VzN9ojYYxFnIBNV5I/NuFEf3EwuDxkGnxSeZkBQQG+6oxkduKnt0iJ3sCZOmzkYOfWkdEVylp4Ii6Btq7Qcj3pDCFdB82TxgnI+lTpIJNoV9oTg56ilchgAwU4PUj9SKDFt3JIUC53BR6ZPU/hTvJUruzsfAIA5pI2Eh++ANvBI9KuQj90d+WzglmONw9MCghtleKFFC/Igx1I/ip5UsAc8dNvXH4VcKFpVLBBuySDxioJYsx4iQ4BwSBgt+NFiUyJIEWIbAu7OOB94fSnmMbQVJzzg/8A1qkQAFQ6szccHsB+tOY7QpDYyONnTnrTCUuxDAoIw5AUdeM4qaOKMZwpHOd3HAojRQ53EkZHQbcfX3p7IQVlIITdtA3c0ibt6DQoAdTsAx1x/KoHZN3yqO/J5UVotkkuHDgHLK5PIqEhGKsSVVgdy/yxQECCKFVjIcbS3HBxk064hSRFVdyEDLFhjHbrTkj3Rgs4VQ2QqjAB9xn0p8Sks0alWVudrNgEEehoKvYrxYPyeWXbIyDgjFOVfLXmJGUD7vTH+frVu2WUS+bGwjPIwMLjHvTZFchsBWycghh+fNBLkmVdokbMkYfjIKgDA/rUyF5GQDzCUJGGbPHsev5VNb5G1riPKj7uRgg/XvmlJCySI+JWcYDtztP+PaglsbIrmCSaAAFjtCDnPv8AjUAX5StwmJgcrjhSO4APINWyhET+aHjiQ7QT8w9umcVFcGVFABByMkg5OfQ98UxLUhZ44VWT7MMpggkk5PofaoLhzNEPMijKS5CbGwBnqM/40nlRSRl1lCuG6E4X6VZmtlig3iOTYVw4wfl9D70i3GI4ySC3EEkZBACqynkY6f8A66YsyG6DLKck5diuCp75/Kq0rRRyRucl1Aw5Jwwx0xTkl2SrJCGKscqTnn2+lBPJoRzSCK8baF3nncp+Vj2OKrtKdzkqfTk5HPp6VcljjPmFQm088HjP0qNY2XIY53ZHzDgfjQaQatqeeXEBCouQCRzjgirKF1i8tGO4jHAzgelJEiPjzM425+bt7VYmZQFWFT0wx966SU7bkW0iNFYNuHJPSpIt0qMX5GOQD2qSZpFjaPbktjOOcU1YXjizkbT029anYpPmI5iF6A7R1IFMy7y/viQi9D2P1rQx5aKTgKxHy4qssaysyEDauSM9Klloc4j2lYiFHUYqrMS2RE+1cYY54PtVjyMF2VjjqB1B6VV/dxs/mZwuQMDqc07kRj3I4v3cDO65cggA0kCMDh+B6ev0qxFFkbpTlFB4H9KI4iN8rElmwv0FJu5dxEQIqjKlSe5yRTjCAhVJF5IJVRz7VMLcFMNyw9Oo9KcU3yZOCuexpEydmRtDsVdrblPOCe9QupZ0yH8xjgEngetWxL5cxIGSvzHuFFV1IEeZfvk/xc4+lA0iOCEed8q7sHkZ/WrMWySVUbCxq3TuaFYg5XawPDDaBjjjFPkUBQeXbjdkc5//AFUD3LcZ25j2nDHO4c1MqgQuiLuXdggjBJ9CaitYWHmrknK7iP7oz61aEarDvBJk56nsfSmZtEaoTAJX4kY4Ix29BQqh5mjUjG0fMD0NXMjygsgBYDOAemelRptSVyw2L04HUYHNS11Gn0G2iMEmOA2emaSVGZVwDywxt7n/AAp8YGzCZY7slew9qsWyM8aFsDbn7valbS4yCa1RWSNU3Mp67sbjVSKYkowyEBAJ9c960ShWVC+4RLg8HnGOuaybpkgZViP7wY257H8Pz5pFRSbsWDfBS6xqDtU9T3z6VRWcIqzFyA+VBA798Vn3MjxyMm/97K3AzyPXJ9KivVlikSKOVSijduDAgc8VEtjuhRtqXlmaWN9pMcak42n5mJPH1Iq7Cw35l4Z8KMk9PX61zqzYlh8pGl8wnMjcDI747fWrUMk+yRbduH+YueMfjUqVty3Svob8Y2RuxZtqtj5uv4VbtSXdgu4qRkE8EYFcxYSbCrzyxErjBJJJP/1q6K1kaVR+7JcrvGTx6EiruYVafLuaEOFibYB0GTnNaFun7tm25LZJX0HuaoQH5Mxq0Yx8yOBkYq9A2bUyEqyg7SDxxng00cU9dCSL5xgAgkHGP5UvlgglmBxyF5/nUafPkBljUMDhjyKA4ZR8xBOST124pk8rJHAaQkZAHygA5xRNC2WBCkRYyAvNOXaZNz8oxHLHGPXNTbSGHyoo5PBxx9fWqiiLkMbxjG0gnOAM+3ekl2q8QDY+YknGecdKdbLuUYDEfz96muYWRY/NztR/u9Cc0mmLm1sRuVfcrudx67eRjFQAK0qBduAD83UA+1W5Y8RsEIJGASPr6Y+tRsBFM4BwSM5wBgd/8aOVjXkQbFmc7ACSuGTOMfnSRK6OzhsD+77Z4+tXEjL8szuJP4j1AHvVcjaM+YNqfMoJwQM9QO+aOVlJt6E2RsJGxWVuxzj/AOvTWUuyj7w6tnp+dOw0aycI3XBOfx6UoZGYAvhVUBe3X+YpNEkJjQhwUzKWBL7+cY9On40whIhmJw/RQHXkevT+lWJ8B4tzoOmWGApH4VZQBCswXCbsgKR+X1oSbHsVmjkESBRhs4O48nuPwpZeeZEG6MbmHByPcfypjxqZsAr948dwM598UjiRlaQEscbdx7emaQiGd0ZZPJi8kPjjHfPv7U6aJ4dgafzHIwNowNp9aeFby1kZHSInOc8ccZ703z5zKD5aK4/iXjIx/OmUipEYxcADhQCuZBkN+VSRRSeZtJCxt0Abp+FNuHjEiyQhipHzMfm5PbGBU0bqFVYSw4+6eOaRbfkRRp8rIADF94PwKA29YkB8wEY4FSyRncq+WFkHRu3+FQpE4m3plSR+FBKjfc4v7NE0TMztgdAehp9rb/OqEhiQCBjFTCyCw7NrHp0PRjUgWSCRSRlwcda6RELx4kePdtUcn39qfGkZuMRj7nAyeM0xozHmRiNwP8XOTSQRnDqMsSRyOMCkxp2HIJGZGY7xkj5jzTp5Wgi2LGCTgjjp3pbNH2r5iAKjcKGzj8asW9u5WZlJHBBLclueuKhIcnZlO5bfGyqgUkgHgjOT0qCa3jEO7hMfeJB9cVf2KxAXJ28fj1yarHJjLsMs33QKGKLbIDHlViwULZ5z265pQmAFLtgYIDe1CyZwpKE4IAAx36U6ZFAjBP3fxx65pGrGQysWLKgGSQT3+tTLtEZIwVyAGxjimoGUF1YqpY9D2pVBbcrKd5xtx70EyVxHSNdx3MAy9CPbNQOS8Stg7WONuMYqeX99MYmbegJO0ew9aWzTbIgUhuf4hnFBSaSGpGskiROpX2Bz9KkUBpXIOFJJC/TjFTEbZP3WCsedxI5yO9FuchYyMsSS2RzigE7j4hJlUVWDYzuLA544qZXP7qRmyM7SR60IythlBz0BzwKSxCtKiOWIBJYZwM+1J3WwrFlUESncFCuNxA4zSsjN88nCkhiOxA7UjuGAOSR3Xqee1TxRtIFwA3BA98d6p7GW2pEiEWrjGCcZ549qekZV4ghIGQCe3fnH6VbWPYRERkBw3FVlDMY3bJbJx70re6NSEv3YxNzt8whAAc45/wD1Vz1+4WZlUqbmVx8w6Dtz6Ctm9mCEh8hUYqPTnrXM3Ra5NxJKG8wK7Lgcjb9azZ10Y3KV+JftTSKdyf6sSAcccZHrVZEM0Hk4Jnb73YoBTzNLLCis7rEJMBSeMntS3OmTuEniJ2qvz84284P4ZIqHd6I9NRUUlImV7l5vsZ2mRYsKIwG/IjpT79tlrArBy5Ox9r5D9+PpU+npZ27rKs8qzRlmYRx8jjjp2zmn2Tyvpk9ykLLbCQ7JlKl43I/r0ppW3Jk9bktxaWq28ISZjE7k4LZwAeQO5P1rQt5iJIo4bSRnf5QVOSBkHI7DgVlXWoWtxDKtvbyb3OQTJuHWt77OUhsxLI1mdhkj8wllcEd8dPpRbTQxnFpWluavmq+DAkiqUwzBwzO2QOv07VdtpjNcqVcOf+WhI2g9qzdP2ygI5WF4mKlS/wApzg5z2HHFXAQm8ef8sbgFQN2wk+vcdapHBNFh1VLkKwwWG05IwT+XNW5GXymVN+7btYDvVVSJ2O0xjOGUqO4JzU6xpuzuAYAde2O4pmMtiEuh2x/xgcgHII4xyatp8+8DhFAPUEK3ORUYDC4ZAAu5QcgdB7iphgF1hfcGUNnPPfiqbtsZjtg+yHAAkRR7fSnaihNuWJPmLhgAM9+uagEZPyhSQQQ2Ccg05JEYJ5vPl8tk4x/k0XuiFHW4RL5sakZK469vx9akUgsW4UyfIuOcDp0/OqqMivKiSFUYfKB0OatR84LjBhA+Y9c+3tQncrYXapbaSFjyGyMkj1HtTGli2SfMHAVtgAHAz0I7U7adkbuWysfCoeMH37/SguI0PnFdjNlmA689DTBWEjjCshCpg/OCgIwfX8aV0TKusBKbdu/b949cfUetS28alDjJ3fMh3dB15HerDiPaJPLO08lF6Dk9O2aCeaxQdXCBhsHlsBhgBnn+XtUiW4lDSNLx/Ep4654HvxUkxjRWKsFPPB6dPQ0xXRgoZdygbiU/iODwRTWmgXbImZmGVdiuenfHpmq0xcuPvBG+8o47/wBKuO58oMiNgKBtDYHv+VNMoMu53Jfn7ykjpxx/WokrFQbsIrGezZ2Ein7rKDw31H9RUN1bYLBQWUdWzz+VTMC+ZWUKc55GeajCGZWZnQEjGQ3P5VJV9dCugIbJSJlVSAjEj8KT7PEku0goM/KByP8APSpJI9wBR2kUdVzzj2qMxFTKWwJewJwRQaJkICxhUYlGXIOBjPv9afKpVCVccjjb39qkJG3ZhGAIPTn86BAxjBO0g9dvY+lAXOZ2sVTfkIvJwTyar3JeWdSxYLng+px/KrkKLHC3mdWbJC1H8scaqzMdzEhf7vaugyTK0aqd4kGACM+g9TUcjhZiqEhF+7joTVk+XFuDFlLqG3YycDjpUNtEqEvKT5oyCCOnHag0S0uTmJ3RM4G7njgVoSMiRbUY8559ucD+VVgmLeEbsqzEKSKuwwAKhdskEgAn9aErETZUl+SAKp+ZjkY6kdCM1U1EfKEjU/NwFHPHv+VaLxwvdM0qBxCcgkZwTxxWfL+9mcJtUEjBBxx34pcooszryNoXj5AyAQwPXPHWpCqvIilgwxjj2qxewhJl2rkKpIHXr60kVq0crZOG2jp0bijlNOYilg252upBJ5PY062cRzSbMK6ghTng81aghCvKH2shXGWGefWmmPEbMm1iCAG9M9qVgjJPcr20AaUgAFDncW65FN8tYmIYEMw5I+tTIuy1Yc7/ADNzfT2qzEFE0e9t69+KkpkMXIk5wpIyDxmnyq7AMhx1T5egOcj9Ke6l4WMeMjPA606FWVI0mQ8Nndnt2H1oBFeKPYGUdvmIXqx44q1ErbyXTB7jsMjP1NQt8kJYRsGdsqCemOD+pp53FTKWO5U4C85PTNBRKgXy1bIKsCTzg1cikQKeQFHpk85qgbdk2I23Jzzn6cVal2oAS+5nXPA4xjikmS43RO1yIkOMhuVGemfX9agil2vH5gIUKcnPWmz7j5gUE85Dd8EYNRRsfPCk/uwm057nFO+thKKSKtyDPbCJQGeRxhs8n1/nXO6p5lu0cKPjrgsfunuT7V02pr+4URIFcvjPAGMY/DmuS1gKqhJUAG4/MDznuKiZ3YZXdiJYDf210sEsQeA7kaR/vY649zVhbwtFaGTLymNvkCfLtz3HU9KyxbMkgMcgjeVcR4yd7Z6H0rX0C/NlqTXcrReZGgVgwyGyMYHqKmKud09I9y3cWP8AZ90Gw39nygKyudhPGcEHnr/SrVlJp8mgP5F3Kt3NIIlsUTCvk4ycdRzms7TNREOssmswyyRqr7InG4ozL8pwaL6EDTLd9PQI3kiSRoX34Pq3AwSe3arTs9DPlk4qMtPMvRWK6QzrcF4LrePKcsNqqeu5e/FdNovhm41OXZLqsQggGE+YMQvBzxVTQLi0uIbdLuI2l7EjbzMoKyjHDA9x1qK20qGy1yQz3cdrCPnRZAdkoP8ACdvQHFVyqKvuclacpcyvZlnUJVW7ZESMeWGgknUltxB67R6+pq40tmR9qVFE6xKCkLZTqORj+IVBa6lEmovaRSQWyHJkmXBGduBg9wR6+lWHsxYW0sC3sb2rNhBtDYDc8Ed6l66rYyktkx8G17pjnfl8A52tkjp9Par0qM8bKVUOAT8oxn0B9Kz9PcFXWRwwAG0MOc4HP1FXFwFAkwJFzllzknsT+dIwmtSeH95HvO47lHAYj0xU0srJIhC8gbWHXr6fkKpxnaikZUklTxxzTAXWZsEkbtvy/wBfzoMuVlp7gySOqbyoUAkc4H+OarkM5ySgJIU4Bye+aar4eTcGBDYHvjtUPmeZKNmNwGAOnvg0i4pokLhb6NgjYxnDdueOa0rdipD8KCo53c7SDxWQkj/aN6MMhRnd2rS3HyW3cbxwWPTinsFRLQtSNhN64dsBRxnaMeo96YDvYoHbaEPTr7nnvShwzjdgdd2BnIyOlVtqgoxw4LE57A+h56Y4p8xkkTW67iGkzvxnnOMev5VejykBVEcZJyq5wBnrzVeUBpMEFm2kYAwMe1BfblfnbgYBJOOe1UQ1dk7gl1Mb7Wb26j1/HNVnVWKBl+XIPHzZB4NTiVWHLDgEDH3iexz6UoLAq0YBVRgHtn64oJ2IJUU2hCSMSCQFzjGe+f8AGoYggQlYt2GA3McL+A7fWp3lYAqoJ285yMBvWmOu2VCBGVztwucN6nFDVzSD0HHAWRx+7A+9luuDwc+tRHe6B4QmHID4PJPrj6VIWZ/9crIXcg7jgYHTg1I8IbncrRcAep/yaTig5iu6QxtuJbLDCkg4JH8qrqQWbCq74Oe/61eMITJYr15U8g0yW3QQptB3L0IHU/jUlRkiimCAVAB7nOat5RX3SEbw2cnjjGO3WqyuAcKF3euMAetS7G3KQgJHOAcc/WkU9Tk3kLSbVG8hQo6AfjT5UVUjcYI9d3OT61XiUkOhVkkbLEZ4GRxx7CporcQRYlZMR85PrxjH510E7FMSM90yk9SAMdj6Z9KdEhlJVlBYMzHjk/41YkTYxZWLqBjAxnPrUtkGwGQscNxn6c5pmvNdFoRqsa8Y4AAPpSNGDcIqsFUep7eppISZXZpEACjPXipRvLFiU3K44JyBwf06UjBplZ2YI6r8xXjKnG4c8f1qtEVMMrSEAKMAeo9qnaJo2cvycEsCe9VZ1Rdigcd+OetMtLQkjUurmbIIA2nPbGaazss/ltwm1QCCMDrwPekUeU67NvlkjAboCevFERaURqnDZzjPC568UATQKSx3KFiwQecZ9OaYoLW7SBgDklj6f/qqUxozqEUM55ypIx+H05pYYWR5FyQeoyPvVLQiKRBvwQOeoOen+cUy4TLx5UjKheOM47+5q9hRIvDHcMgdSP8AODTZQr+TgYUMWPP8qLFXKNsqiWSNkG8jALc4JJ/pirgcvsDgF8joO4x27VWkiEciOCSS4De+eRVuMs7sHAQ7+nc8ZP8AKpSLcuxHOGZeV3sGIwQaFhVVKggKyhfxFSoArkM6rkgnvUe6dGJcAc5JHOc88UNBGV9B5Uqu5WByofap7ZpzKWlOF37QG5HX3pqEJuLH5AQGHcZ6fWpVwfs8kf3iWB4xgdvwoG5DpYmMrOMBHONpOaIwGEyjaGGRt9QOpqWaTbIA53Adh/j3pjHAYsF5zkge/NOxHM2ZWoiSS2kXA3Kd7ZHA9K5i6cSW0+VUjjaD2xkV0+pzSJFI5wN+UIPPGO34ZrmraSNDIk8JMbMvykkHB9DWUz0cNtfsZrl2sVOFDGQEf3n9T7cVLFIkFixCtC8YMke4EScHoD6VY1+L/Qo2tYWjiEm4M3TB4PPtkVn3DNDGFeUuZ16DoOefzqItpnfBKok+4+4uV1W8a5nmZJ3IBkJJAwMf0/WtTS7e9uLa5S1gY7ELOIxghcY59jVSwsWBDgAovXHQfWuhsUMqXUiSSY2Ahlwv4f8A1quKb1Kre7G0SEWN9f2sNpPdpsRgluWcNyRkAd/b0p8Trpz/AGfV4phd26t8jMCrEepHapNS0pU0+K5s7W4VwVJkZ9yuf6D6VFdanHPFNHqNjJbySpiCZMlQeM8nrVyVtzjfven4mnBHHYQ6fqsdks0RBM0kmPLw3RcdVI6VYjMMkl0tyiwRMDLCFYhOeuPftWNp4sLiwiQyC3eNsMwcgvkn5mFaU0EcWoRyWa+ZAynfGW6jAJx/PFS27GM0rtPcvWLlIyHLFs/Kw5yB6+9bFsN2TkMwx82KwbeaOWE+QGWJz8uRtIyeRW0pKEtuw/Azjg0jjqRaJp/uSbz6EZ7j0qFn/dM0ZUFhuC4P5U4zNIGXbjdx8x+XHrVeVisZxvY4GNppt3MUpCKFjRmdiJBliQx6mmRjCopQM7DKn04omkBXds2noQx6ntRbL8m88FeMMePwqTWKa3EQMl2eqsV6Hr+PrV1JRIgWPk9cg8fT8apSD995sXzEHk4zgVZSLy4/3Y++QM0BUtbUss5LFzFjgEAk4Pb8KlTaIwCSQrFSx6nNUZnUIxIAz820c4xViGSNtykbgozuYelBnbQcrZkdRheQBkEnFT2ihYsx7kLHIxxkVXlm6LhnPU5xuye9LaOuyMFWY9m2ZJ/2c01uJ7F2HEaqkaldpPBbuf06VE1wW27hlc4G04zRCFEbBs7j1XoM9enpU4RJArNGBJ14OFFaX1MW9SKWIvKF3D7uAu7FTRxqsSeaCwJPK9GPsO31qBiIZHIZX3n7q9wOOhFXGdT8p2KxJYdhgD/IoC4i5kdyY1CDG44yBUbSGSQpFCqcAEbMHH+eaZGwJZoiA39wg4+tTbmRdykFXOQfU/Q0bCI5vlSNC++RByWzkc4IpjEfxBsc4BAGBTnERY9iSCWcYw3fFKUhaFsOMcYxySPzqZJvVFIqSoCMYAYKQCeD+dQsHXCnAPU46Z9atwW7BlkyJABnc3BA/rUZVcnBCbjyc8jFRtuaJnIeRhQ7AklcZHXjoRTinmqqux2g5LA9vX+VLbb5V4Uk/wAIHXHv9KuyoiwlY8HI5VvX610EuTTKscI81VTlFYKcDPNWVYQXGzBKlhnGM9/6dap+ZLDKzJKwb721f5ZFWoooJHeWTKjoMEk/5OaZRJAqunyOEIbZyOec9agup9qOUXEobLsRwcZ71MSqMWcHlyQ2DyelQkxuxbBBAx19utIW7Ibl3ZxgGTnJIGARmobhY7iRY9+ZFYkKPlJFWgeqBWJY4GD0GSajEBb5zgbj8x9O2APw5pl3KQaQXEcmC43AAAd/8asR+Xhi0jJycjpjn+dGCsJjVSuGKk46jPWorXKljJEu3duL+mO/PegB7zBOQVDHhQRngelTxTF2C5Vowxwfbtmq8kgkH7sqmzkIoz37+9IPlEfmbRGxwCfr3pAld2Lkcixum3JcqRheOT0/nUO4LJGVJ4U9egNPTbgrIDlcDcBwMen6VOIflmU7gzN24wcfypMW25Xhb54w6jarZwB36f0qaMNsJPyl+rHsKWRApDuN+ecdAM//AKqdDK5MiOwjOWAB5B9KLDIowd+Bw3bb1x6fnSP+8X5crubt6EVKu4jEbbWzkgfp/WpEiVAUck9uccd80mCdtSvaoVjkErhmBGNw6gd6kBR08vaRjBz0yDxgUoDPHkKPnBz7dKUDJaMjGMc++aVi7piyNvCgucZwMDp7VNGjBNoVSWIYN6jHeogr4EoCDGGAxj9KfuLSMBIA7d+mB6j3odwsuhm3oeMM0Zw4wwB9uKwbraYm3wxpIr7l2jBAH0rrrja8MvnBi4b5sDqfT8axb+3WOERgfumY7TnqCPu+1S1c6Kc7aGHeu77onjLSEbhGeMk4PT3rKuSZILeFhgoxG4jO7IGPyrXv4zHApuELy4wsjZ3DBAKn8Kz/AJYG4VpoWXdEH4ZMdRx6Vmenh5JWfYuWWnXrWx8pw8RO0gHBP4VpWUv2S5iSFX+04wYHyUJ+n+elQaFOgwxcLJjsRkiuj1KxiuFW+tpVEsSjCjpJ+PatbXS5R1q65+WXU2NP1kpZw2k8drHMo2MVYsxUgnO08HHfmsRUncz2BmcWM4DnOAI1zywU9s+nNXIEtNXghe8YrexkAR4Clxnn5gOtZHiCK0tZPs8EzcHIiJL+WO+e2T7VpPY86Kipuy1MfWdKFtcSCwuEuERvLLL91ieQwq5ZrJbWHkN9oW+Vyyq6DAHqDzmmbUtpbSDyWdpEYgAiQMp7juPpUjzala3McbgusalYzIApQHqDiuY6pNyikaFrcrFEhcFpCArtwT+Xatm3Zs5fITH59sVztqm8kjO88HnI61u2pKoSc5PU+hFNHHWSL0MgRRtJAXgioJMIm/jO4seacHKupJOSQFBHUdeabKv3s4yMkfWgw2ZG8xk27FzETwTzSnzGmOcYJwR2x6/WosFF3OXbgD5euKmK7I92QCTuxjBI96B6dCzEu933nncNuR/Kp1C4Xdy275VIweKhtkCsBlMnoODkmp1AUoGZiwPXp2oMJbla6YkLzsGcHA/mKH3iPKOOc8KP0oumMhVWD8Nlh3wP6UroQnGc+rdgaDRdgjkeSTfKFb5cAjGM988/Sp7Ybh8ki7B/eB4NUE/uoFy3DNjGfWrkMm2YKOQcdFzg+lApq2iLVuZBCMbsEYxtz/kVNLKu4IpyNvRVPFVd+8bkIznn0+tIAu7eWAZu47j2q07mTim7k8c29k3BiG6LinlAQoVwx3cszZwB25H6VAzkSo7r5bdRgdvoelWU3ALuVWKtwGXBb3phsNaJmlDHcXPJAOQvvUqxqrhiiquM5Bxkjn8aaMvIzD5pCQMb/l/H/wCvV22OYtxjBySN0YAx7Yp3IbtsRi3+UyDawJ3HIxn8KjwWwV/cgMG4HerThY1lJRlYqQFAyenrQ22YblYFgPmJ45HtQRzNlKSaNp/IM6ed5fmbM/Nt6EkelUrS5jvLVpYZklgkfMbxDA29MH3zn0qpcS3um6pcXFtb21x9qVBtkuFhdGX5eCeq/wAqt+HrVoo7m4mEJnuZ2lKwS+YkRwBtB/DJ+tMpS6HNwqxhlZGYMHOFX69vap4WVo3aYb8HO0jg8VlRyyCaQAEkYG4/w+38q0LORxI6uuEA6AdRjrVmjjd3GTbpnjjwEkjAJK85yf6VoMkJCKTkDCndxyKoQRSRCVogTG2CEPcnrj8qtSQs8aByrMMMF3Y570hvV2JJkSXaqMA6uQcE4wfT3qo9uUMq5GWBAzwy88Z/lVmOMGTLyn5eRt4A9vepVffMH2kPj5snr35oE/d0RRto2RWRk6jGQcEZ7j8qIQoWTf8AfXODjP8AnP8ASpp23OGEhGOm4dPw+lNeFVXcxY7SOg5xQCdyCHO/EmAM4HSm7FWFtuWCtk4HHf8AwqaRC5LkfujySOc8jpUPmDfIJPlJOcL3HbNAxsSBX3ElmxhSByPY0XCqyxkpwcnBOAadMVGdoLNINwK8FSOoqQQxAbuOD1I65BoGnZkVtKUdmK75ZF6MOtW0LPyzAseeDiq4RY44pE5dWHHrnr/SgOhLxpz945HBA5pjbuWAd7BGBBb7q9D+dNs+TKTGy5JPXkcYoR/PIbAVhwynpk9/zqQKXdmjO0ZHA7fjU21JGRuMlSc5HU9vpTkLOPlI4OdwH+NJMm4ZEZBVcbvfvTbdP3zOMbWAyo78dab1K3VxGRAWJPlkk7cnPXrmpHKyPEDkZAduepp0qg9gsmR1PBB/+vTZF+VQo2uANw9KV7MNCWNlRc8MpJAxjgjioY33yIHjJAygx796njhXYSPl3DPPTNQW5ZpDjKNtwCOuR2/EUWvqCdid2zC8bt820Dg98+tV5FxDCXgVlHLDOOOmambJKOgw2cex+lI8DDehDEYyM9s/0otYadzD1HJjkFwzTbwBuHB46Y98Dv61kXXlEr5OWgDbhvBXnHIJ/wDr109xagxS7gTKcFiQcNg+3Q8/jWBKJIUdA5eJwUw43BfpWDO2lJ23OfWJGm/0SQs+cCNuGH5da1bfXRZ25jSeRZgceUOfw9qgbTYCjySuYQc8Bs4919aifRoWsTdoZJNhwziXJbjOAvXihNrY9BuFRJNl221KBpbm2tre+GoSLmNQu5N3vzx9aSFtR1BJrS5WISMcZlOGjAOSR6f/AFqqsYYhEDKGuGzuePckifXNXJ4JLmKBkk8uRehLZcqPX1ou3uxOy1j1GG6ntbtbO9KXMEXyowH8POCpFaNiZ7eYSRmPaV6tyefWo5UEs8UxktmkUBcKu1SuOvtVwSyfanSaFIQ75Ub87eOo9v8AGkYTmnqiwrGTHlIq4wCEIwfXFa1qVx2ATrzyDisqGEjJB3RsM9AQKv2iY38bsLj2/CmnbU46juXvk+VmPyk/Qn/61MZVjGP+WjdOeKTO5CxXIBxj2pvLMzjlQcAHvTbuZeokjLjaXBwcYHUDsaktG+UsT0OBgZpJId8gBTADdAwzj/61EZKltuCgPQjBzSE5JIvoybSdxzjP+6aibJG04wR16/WmE/KFyF+bB44ApRt3NhUY+56UGRGrMMkk7vug98UsvyQ7AcuSBycnGetRW6YjKq2SxP3h0P8AWpQoJkDELyMNjJH40FvcPLdCSMcYwO1TlAsaP1I64OCKrJky/OzELgn0yeMfSrQfLDeCNoyRu/zxQhSdwgYlmcMTk449KlV8hQjoQCOo4PvVfCnbvIdXJwB0anhQiKiYRV4IPAx6Cq5bElwn5t5A4IyVwak2jacgZPJPpk+9RJgkAblY4Y+gH1NOdyUAjy8pJzuAAqmRImQ+WNrF1C8FQB9cginqSzpkjLjgDHX16dfamRsxC+WsSkcbmBXA9qnjkELAgsMfKST19R7fWrVrECygxph8AMchlPI/wNMKIXBIIyv4/U1Mx8zBUoFXkKMfnn1qEyRTxNDKSsTjY2wkHkeopNCWxgajBEms3klxotzqaSIhWQRCQRgDBABP0NaOkPFDZTeTpx0zLZ8p0CE8D5sL/nioB4cs1J2zahjoT9sk5/UVc02ySyttsTSyZcsTNI0jfqeBSCKs9TkLeNGhV5t25wc8Y3HPB/z6VqRrtAEYVzgYYnGQO3+fSsyxTO2COQtjllJwGxyMH8TUyefE4ZHCBDjHU5PU49KsbJ3T50dch2Bb7ueQf5U62lAceanQEHn5TnpipVuniKK/zAEhTjgCklBgmSTbuVgcZ54z3p2uNMSPM8rhn3IQQrg/d5pJIvnnjUNhfmJyP1/GrHmqFYQ7WOQcrwCMY/xquwEs2cfdQo6g4H1pA9yBjiSN0AJBB+fOOD0omLeeXznJyze/b/PvSmQySAOPunaVK/qKjkBWR4wQqqCfXI7jNA0TKd7OisqKSSMg4J649uazij/eYja2GYHkrj0q6Ii0gxIWA49SajlQYXawVV4PI7f1oKT7jIfLRI2ClguDnGM4PPtinPMPO8tVP7wEhcdeefpUSxsbJowT6deB7j+VSvtaLepUlQM44J9eaCrJkYEZXzIn6nBPU/h60sKlJUdWVcH77Dkg8c1I0UbRRMAVAClghxg/SnGT94Qqgl+voBQK9xHtWV4jES4lyBjnp1FWzGI0XeOc4+lNTakKsB83XcTwT3p9rIGYx4GG67u3rQTIYsWdwDYByDkZz9KiRCkocn5exHc1YlX7mwrkgjP9KikcNuAzsY9AeCP8aBx2JHWMxsFBJ9Txg5/lmqskpjijbIWUcYPUjNPQy527lwxyOcH070xo1cI7Mo8v+H69x7UFJWLKKVQYcbW6jqM9xSLERLvyvQEc+tMglI4BPX5jjqfX2qYv84ZF2Dup6E+uPSgBVjZpiTwcg4PT64olyQ5U4OMHPGR6Gns+0EFjvxx3/AUqRMzkAoYycgY4X1xTC7RAcbN21gp4buT9Kzb5YwDDtKsRliON3+B5FakihztL8dMKcfQ/pVW7Q+SySbXZl7gYA9CfyqGmaU2c8IPLmXJWSFyQv8WfqO1UTZAT3LxF43+YxKF+RsdRz0qxcwfvw25Vxxj+8R2FVTay8lpxtPzAO3BJ6j2rBnpw5raMI4be8AaYKXwAuWJJIPTHbNWJLK3EqGA7ehbYSNp/u81XhknkljkULvGCQMZHbPSt2BpViGPnwfMwwABbHPPegdSbVtTM87zGaImUTZyQcFc+uBWlZxKz/uQWI5YMAOafFnaoYB1P3cAYGevIq3a2qwsrFEw3IIGcH600c9Sp0Rbt4kjIKoOB94f56U47lIEY25HGOKl3BhwCgPrzj8KRWIB3EsuM59atLQ43JjWTMWVUEkck8Emi3+TJIzuH5mpBNleV3Z5yV60+Mqyoykn3xUtWE5ERLKSAPvcbuOKagMmc8Fuq+9WwqqfMJTPOAoprfu0bICnqV7n3ppCck0RblJjQnIX+fSpEGxPmQEtnPzYqBSdhIBOT8xXg1KcsG3Jwvy8ckGruFrBGVMasw49cdKdLztJIA4wP61LbIMNvAOeuTjrUrKpXY/3wdu4dSKlpshyuVkjBDAFfmb5uME8dalLqT16ckj/PSpEQIqfMRt+b1606dogy7Qd+ORinawcyIJUYSLgB3H4ce1OAbIUncM5C7OalALMmQC+eSeCAfWplVcZL7u3XB/D3oDmIgCsjFemAOB1PrSvK205JMfA9OPoaBCWJ2gYHzbckZqSNX3Aj5GIBbA7f54oBtCA/vNoUOhG1c45/E1bjcK6BsAbe/IPtmoI40Lg7cq55G3AIqwyEIf3T7CQRsbgD14oJbRI8iqihQuzPy7T/AJzSR5LLI+SuPmUDbxTGcFmUncmPmzkgf59abvMOz7uW56gjH1qiUSHULO0MvnzRxyRx+a6E/dTPUjriq2mXCXhe7ttQE1sSwVTGo2dOOBnI56+tYGrWYfVvLlu4Bb30sUkkb5Eh8s/KqgdVJx1ra8PxqEu7iSSCWe4uGlfyj8iYAXb7/d596LaEPc5dlSNE2mRF6qwOMn/DtUsEj7+A5Yj5WJwPx/OoIHF1Bv25IH3R25qzHJ5w2x7WcLzzjP09a25UWyw04LhSGQk44I60wQyKztG+TnKg9AfcUyJopIyZGISIgnAOVyP55qYSIIi7na56lfX6elNqyJvZiI8gAMrKGVuVHbP86an7t15PYuDgZ5NFwnmO207l4HK55x2qSJmSQIShI+8QOvHFZGifYjlcs7CJmDDjJH3f/r9Kq+a6s25cE8gDgkd8+9aDgFGHV149Awqgy8BC2CRwG6f/AK6Y4a7jZJmjAVxgOPmIOSD25pYSS7FgGTgbW7dqTzUeIII180HAXdgEelQO7mWKRd5AypQDAx7UDaJwdkTxcJnLnHt/Kq6FigAwJh6j1qK4laO6DMpYNyxx19jUls4EPmRAqFXJB5K+1IajYuQuXQs5CbQCVx+VTEpsG5dyEZIXqKqRssiLIzbcjaRn07Yq2r/KC6cA7AwHQ+/rTIlo9Bkr4Y7k2r1yOlOtmWUqE3yBWB9OO/40XDiSN484wQMMMZHtVJH8pWXJznPB5pDtdF+TJlJUlVI4JHT8KhlUxbDyQvzEE88+n+fWnJMsgzvJXjrySKiun2qAC4ZVyd3p9aAinsEchYEncwPTHODT3haQgIW2jp6n61X5lCcnZ3UdvfNWY3KuUO7IIy3QUzRqxJasoP7wkt0zjBH+TVqMLsw7YKqSMjO6qyPHlTKAhOc56D6+vrTJM71eFgyj5evPvQSyzgqOSrAkZGM8+1PEhO4MpJz91Rzioo8xsMtuXPynrT3yJskhmAPXtQIYxxKFA5UZyF4FJcREFsr8pHKk5Of8KlxuiHy7doP3vekYo2dxIOcjjBNBSdtjJuLMjpGNnfB4z3NUzaNC4iCHZJwvIyR3yT+lbaBDKwVyQx+6Rx9KakJ3hMHafXBAHp9aycOp0xr2OdNjLMQ8DFo0P90gr6itO3VkgZWbcFx8pHAxyMVomFVO5CNg5bDYP40iRhi2xQTjgqcAH3qXEbrORSt4pHUlQvzNkEDB9+KvBGk2tIrAr0xxmpYUAGCSQDnBFSyDumNg7YoS7mTld6ELykLhuCw/KmI2WVSGJxjKjIo8pfOWUcs3DEZBA7ChkYKGIYgngtVAkgjxkhyCRwVIOTU8WFGCRgdMnkGoohySc72GBu9asrGCTnDc5I9DRZPcmZHM7GNwvyseGI/nSkmTlyDj07GlMP3mLMiEngdKZDGoQBS2eRxxmlrczJYlzKQN24+nAGKeoAjUKAWY4HvTSCoJQHI4AJ60+HAcfvAFwOST1pg2ydco2ONpGGz2qAsVT5pPw/wqfIHJ3EA/Xj+tMmRNygAKF7HtQZrcrtKeQdxLDHtmpIyMMoYsTgkn1x9KgYHzwGOB2wM496sqACML1PbjPvQaWRMH+RQEyw4YtzmlidgxGe3A7/8A1/pUC4hIdlBJyDuPP51OrIFLyMcg9sHjHeghrsWo3BjIRAe7Aj+VLAzFTnIC8D8/Sq6uI87SWQAYLEng0MwZdrKT/FnPT6cdKCeQlLMI3JU5OM4A59elNE4eLzFCgpghVOM/hUaEFQx4U5O3n8xjvTGDMxKkFMfewMjH4UFqKLSSkso2sRnd6Z/DrVhiHRcsVHQZHBqlEFAwhIkzu4xz+tWIvvFfmLA85zg/4UXE0kYmt2V4moPNDZzXYklt5FaJhujEZyVIJHB6jHrWjocM5W8nuLdbdrudrjyAd2wYC8kcZOMn61h6lDpya9dXHiBJgpCCBx5hQ4HPK9Dnsai0O1itb+3l0+C6jEt07KJN3zWwXq3/AALpnmrIaKNpE0W4cllPG09R7+1XbR1MjhiQBkKV7devrVOJ45R5kYJIGBuIUj296nt5WmjOQgkjO0BWxW1ymrliCFMEE7GcjJJPHSh3LLheme3Uj1pLZlZj5qn5cDJPr39qbJI5umTYuSMfKMce1Ju4ctiwwkjI2swbkhB1z/jiq+zfI/3hKDkjPUZGaJWI+42XP+TSB/nLtGcL1BPTHT/61QWti3E2cSfMuwlhjtn1qCYrNkyIu4d89Pao4yxiwGUgjcMcH8aSeQM4ChSzDBAPQ+uKRKdhqfNKUQAKQM56r9PrUCiRJmG35FOF4yB7GrD7ohHMDG4Bx/8AWNLkMuQMvj+AcUxqZTu9zoS6kYGSQRx0NIrojiRgqZOcHntnirLoHfov/AjziqUtusURCu289gcnr0oK5tC6qKByVL9tpyfXp+dOinw5j3YP8IJx+NUSDGqnBCjHA7Hv+dP81WBbG0ngE9fagTVzSbMkauMYzu3eo9DUJ5YxlVD9cHrTDKyRAbikfdWJFPVFCrjK8cnpg+mKBXsOlBB3jDDBzu6En2qrLKC7rgFyMELzgelWGO9Qqrjtk8c1QKO8hYtjbxkenrQVFiwO8eSuMdAV5APvV/BMQG9fbnFVWVRbptOSMnP8utORmlg2MT5o5yD+VBTlcm2M6sAw5P12mpogXUrJ2HGR/M1WiUvGokYhTxk8EipQxC4QNsHzHPUf40CLcKGNjEVIyvy9qfM4+6AS2OSRyuO3HWq6zZXLjqcBiQSKR5FCfvAXHoPagTLHmLgZVVbcDyMUSIBnecDcO2cfjUUbblRGy3GVAParI2OPlKtkigBweRXVo27YAA4/GmI54GVz0LKpqQK7LnJIB7HpTGO1wDhlPY4JYf0o3BMFDOcMR7ZGPzqVIwCSSMY4GOoqIuX56sDyAvWrG/hGYYGfTgUuVA2yK5LDnCgYACgVG7FI9g5yOOaW5OXL5/Lt+HvUKqGG4ngHODxmoZpDRElu2wFjtOD0I5p0oLgbuh5GaZB8x2kHBOOO1TBFUhA2c8DFImT1IYwqoMHeQcj2NWY3VkJTgg5bnpUXyKSAc9se/rTWjZSAOFGRx35oIuT7w/zIpYDDEKe1NkkyBuPBHXpz602Inb5YYce36U1yTh1G7HAHcetNDQ+PGwAAsewZc/lUo53MXRdq8ndUUDfMJQuCPbtRHvkkJZiSeeelDDQcHUgKRtOBnd1IpEkYPuUHAbnAzRICCQcdc4x2+tRIwL9Pm/TNJajtoWjyhYZDE4OP8KafkQttGMfdBOaZggjhicZ2+hqbgoACSTySDQJ6FVJMtmTgZxx6+lWSrl8KoyO4NRqm+YCI4xwBU8sixR7WO3sAeDmgGEjNLzkAHgbO9TKSqMGLN2GMDFVQwfKnAT2yTmplxhSfmYDkbeetAmTEsOZPu5zuAyR9aajtjCx9Tklf506Z/MUFBgc8jr9M0Ru3lLkgjHI4JFAC2rbJAZMhkXsM59jmpgytGpxjf1Y/0NVI1AfKlScgAMOR9Kni8zDD8CQfvD60WE1fU5jX57pr/UWg1C4tls/JYRRMBujJG9zkc4z+GK1fC8gKXsRupbsx3BX7QWB3gqpGO3HTjvVa/uNRuNWuLayazgSFFBE6M7yBuvp8vGK09Ghe3tRBOluCp+QWkexAPoSTnOapiaOFiZECqSVUqCQOhI7/AF+lXrd/Lk8twGMpBBUgjGKyZJZnZlUgZwWBHf0HtT4JT5WQjgbuGT+DnoK3bT2HvsbbvGr5VARySwOSf/1VI8qogltZGI9D1JP1qrbSbl3MCG5BYYIb0PPQ1Mj7IyXLHoWAwQcn9KVgsx7ho8HjLdSRwB7VG0rNLlGZsY+boeOlPkdTEQhV0U5Cg4OPp3qDzZEkST7qsMDB4YCpkNaE0Y/cygOGfO4A8fy7VDEqJPvLNuPdeQp9KmExmdXi2Bh94N1H0qMz+cyr1J4O7uaQ7ExUMyqG/dc+2DT42McZy3bkkdfpTCmc42xY+9nO3P1qGNtwMcbqWQc80jORLO0OWl2sGPvziqyjLjBLH+En0prlt6suMjqoomZdx3MAhHagpEKmXZliGbqQnINPRQmGLfuyBkngjrTFCyOXT51HGB3/AAqvK7I8keSEXhFoKWrL8YDorM3Q8HrU8s/lqAUyp7HiqVvJvjDh0Ze4qV5EWZEYhuMDJoFbUtK6umVBYn36VHL8z7yTtUcep9OPSqqDkxoMMzcHPf0prXLO5YcFTtYDr+dMLFwI0kQPPJzk/TmmMBHHGXfO3oMVHFNJHv3Z+duVJzQ8hPKEKoNAyyGDCRCfmA4OO/pTVkEaNnduJ6VGZAsoIPJ4496YYgfMVshjwcnoe1AyaJWBXDhgcnJGOKmAxgMBtPIPOTUcaO64BzGAMAelTRhXbbyB0OcmgtS7i8QvuPTPT0qxbsq/OHUgELgd6hDRoMxZAbocHn60O/7obSMnqTQDSaL4aSNcAAR46gZJqKdlYE7hnHHHQVW84YGASOxz0NKJGy2GAU9gOfegnlGxM4Lc8gDpmrcLgxYOQ2ce2KqqDuyenbnmnSMUByTuHYc5NBpYsF1wI9qggZ61ECA+G4yeoHFQPP8AvEztUNxjp71NH5bAORuB45PSs+oWLSPlwVyF9TxzTBh3ynzHHBPQVGfu4Q/L6daFVlQuvAHXAwD9BT9SHHUdKW2kgKWXGQPrgYqzETt+ckgdfr7VVUDeDnaSCTT0lbZwWHOMkcUmTJEkr4VsEL6GoskSLIG6joKbM5XDMMDOSfT3ojXe5YHIxkY9aEO2hNDgR5JPze/JqRvlj3dOMkHjAqOKM4wpK55HHH40hkwwwNwPOP7tDJYfMXJLdBjrSQKeW+UAc7T1JpIsvICBwATzTtwOcjPru4oRb2LKHzFLsxz3qEMdx5bPqD0qNpU4AK7gMjGRx7mkhlIUfMN/UgY5/WkTbqWoYi7bgyk9M0kyhkUnzOOCSM06JW42jPHI6GpXOCFXI42kf407XJepAsbMvBAJ7j+tTpGRAfl+TIbbnOMe3aoyoiYqXLAHIIAp80y7sqzZPIyOaLWARdrtkSYYcYyMj2qwsPypvywGSMnGagLt5iu7MO/196sIwdgCu4H5sCkJ36D2h5AJ28j7vBzTnKI+du75eOOf8KYZQjHO5SOh9KaGSdHiMjfOpU4yMZ9COhoIVznNRtrd9aupbzS729jKII3RSVj45HX15rY0NY4bZjY6dJZpv+5IuCTgcjknFU5PD1sASs99uPVkvHGfrzV7TrWOyiZIpJ5FJ3FpJPM5+vWnctXepwALdcAf7QOQf8DUiyJblmlUn+63r9PembHSMRMhMYOPl6getSAMi+U+ZIe/H9a32BaEy5k3COTaWbmNj/XpmpFka3IT5TjHXk4qvbL5IYEK0S/PnHTNWMjAw3TBI69aZRMWQl5RlW4KqOPrSySKQw3ADqSOMe1RKY1R/nJGeVbjB9qa5PnDBVDuG5t2SfwosBeEcfknyiMtyveopWVXzwjjAfnvTQWh+4W2H72f6UyY/IoVCQepPXPvUysiU9SWWdkZSoZ1cggqeppFiBcMkzEjoOBn86hzHGse9W65BB4FBUyufmiIA+6y9/WpsPQme43FwwJcLjK8Ee1UHVlJYyKUxnJHJNPDxFmXOMDkNmqkwKIpRyx6ALzQk2NDoWlwdrqUX5gvepQQU3EHBOCo70W67FWRXMn94Ecj296QqChGe+cA0+VhfuLGEU4yCeuKddAsQSV3g7toHOKgQCKR2wev4ihJ98mVk3MCRk9+1HKxXTFDyJI24ZZh/DT5I8YAY845z/WlViA2BnHFRRSE/IHGGJz7UcrHsWoUVZQzjapXH3fu06V8ysDIpjPBK9DSE7VHDNgZAJpkQVmbLBS2Tx2/CjlYJpuxNs5IjU7Nvem3HnpCNpUEn+LnipQ/7rrkAbcdsU1pQHUls+oI6UWaC+poWW0w9ecZYD0p4cRhmZVwOQeDVASgq3lkBieOajjlKv8ANwc4AGOKQzQE2f8AVlSMYHNLFG5icydQcZHf6VUzI4VikYGeOe1TRTeWMNhj7Hr9KBp2HtMQQoySBgZ6/maeFyp3KxxzTHkH3iozjA/wpBIGB3bsjiguOw6IkjIG3AyBj9Ka5Y4yrA9S1PjcsOdu4g5GelVshD948nr2+mKCkTCQsAWXgenOanVkkUEtgZxnpiq8abWYsD0znPX8KkZ8OpdsjrwOhpWGy0zbFY88jHFO8zdEEU59vpVR2UjJJ9uakSTKBlO3Axk9aZLJFA3BmA9M+lLNjC/Kd3r6fWqhmADcjnO09ifekW73CPK/IcgheaVkNQuTGcQhvM6Y5+XOamiIyCRhSM5HaqssPmxblY5PTB4xVm3CkdcKB0x3qNxNJRsWEbd90lSD1DUxhuU9Cf7wPOe1PCghgXZcADJprEsCuDu/2ec1WhkhkjEchj75NMCsX35x67efzFPyu9gThjyB3zTVVWchdpwc8etTa5fqOUMCxbAXvgfyp6yADYquB6gdaYzNGAeVHo1IrMTnnBPG3v8AnTSJbbLKSOuMg+Wx45pUk4BJXPUgnmqqDeCq/Lnse1SgbQMe2MHpTWxNi1IzYUgA7iO/SmyY80EgbV7Bf1zUIlBVgEBHueaaJPLK8kKw4B5FNhyssKwYAgAqDwrdD+FT+b5JOxhgYxnt7VQjny5VY+V6cfyqzs3DIY7Sc7QOlRa+wmu5IGkZyRgMRnOM8UjBpIvLSQxuVIDdx7+lCuwXO7aP7qmglWTDsuDz6H86VrAjntQvns5Fgm124WYY4W0VtuegOB1Nanh+6W9s2Y3cl0PNKmSSLyieBwBjn61m3NqJL+/t7S5jM86RzhMHMboRjJ9Dj61e8PStJbXN04iL3UxfZGxIiOAMcgHPGT9ap7BszjLecwHy5wWjPQ+tXoxwfspV1IB2ue3fArOZWRP3oLIRkEdR/jUsS/uCqOQh+ZeMc/410NXIbsWWl+0MAEKseDgkjGOOO340kMmxWTeCMA7M4Jx2qJ5xJDhseap6gYYj1zUce6Z1DkJIMYIGM574peRUZXRd3+YGDjk/xHt9alWHDAM+M8lxyaqNI0MhDNvZWxuUdalS4KyEKdq4ywXnPvQhpNF92YNHFncvUHOKikZowmFO31Y0lvtERKyZB5x1H09qiuJgUMfBPXjoPoaT1JSuWJQJI8Bm+Vd2QM4psJYgfMVPVtwA/Kq0UgG1ZSVYDqD1qZ95QjgoV7ntR5AlZlKcnzN+T83GSBkUsYbCAM0kQ5wU6Uy5YMoK5UkYVe31zTo3Qo2FJIXk9c0R0NXsTSKgjL7gMHIcHp/hTFkjzkEhsfhj1ppZxExbAB461Cvyncwz7H09Koh6llpY5VIB4x0x1qlFsDFJNm3BA9vSnScuSufL6gZ+7Ue1RAu5kcsSB6j3NJXElYUXLK7Kzb0XGCR92pV2yAFSA3bHrVXICkMAMfxdj/jUjyMI0UBdwO5R6D60yiRJZUbDfhnipi4kGUY5P3j6D0qrFKVXjv1B6Uv3G7DdxgnpQGhoCQKhIOUPXJ+8fWoGk8xwQCSxyRnr+FQ+cjEr1wMA9KRZGADbmynIpCS6l9ZNr4kJ9+OlMklDkBXOOQG6EVCJS4Lng/xE+lO81BIDtDR49KlxZRbjeUQKoKuoH1PuaTeGYCMHHboBUDSqFK7c5PyegqOZgrK20oenA4pNNFR3LTTMwVc5GdpOcGrkLRqq7mcDpuHb3rIEpAG1SV6YHOPerVvOu0KEJI65PSpKtdGurdCMdOveo7rJ27N20ckYyWNUvtTbWAC7vryKFuTIob7394ZximSotF95A55QBu3Gcf4USfdXOOnJH86pmXJAXk9gDUayFyUjddx5HqPagu5cJDEbMYHOD3qVMkFRzkckCqCu3PTzFHrVhJJE4YKAQeQaQ3oh8jHcgUYI46YApkLkBgWG5ccnjJpVk86PzSD8p254NOUZbI2kDk/L1oLi7EyMrNnjIPY49sip1fyvmQjOMYzndVUyIFKHOc4yTjml+ZjkhyB0I6DtnilbW5LSNAESEFSqqewNRgMoG3qelQxliXKNyAM56ZqTLopBAHcHnn/PtTaIvYZw0hKZAU9eetIWI2rHkhecY6GmSDI3Apn1AzmqwmeKYBenbjkGkkWldGir7jkAsewPQmm/NtJwwY4ODkAVAZsybvlIAPIPBp6SkDch4yMKeabJaJlbI3PgDGMgjNPEkYI3cg9yTzVfzVUFGAUkbt2RT12leuOOSDz/AIUJWQnG5Ijpu6qmzuBnH40oO5nEzgDsMmq0X7ndh1C4K89T9fepFJmlU4IyOSWxSauUXURDKSMqAMciptwbng49yDVVX+Xy493v8vf8Km3kswZRwOmc0znerJlIbg5J7ADP40kyRQRvIzYVPmZiwwvqfSoFZvMIAOB39RTZJV5G1OeCm3t70nuBjXd59g1CeW2utPIuVRpI7ibYykDAII7EVp+HHR4Li4+1wSSzTGR/IbcitgDA/ACsq8e7uNVuobWPTfKhCA+fDufJGcZB6VHp19ew3Sx3QslU3DW7CBNu1tu4EdiMfiKW4HOJM21QoLBzgKTmpkdI8CSTy89QRwDVNI/kMgZDg/Mi5BH4Us8iuijaxz0br+GeldJiXo+ZWV8MrD5T0pzx+ZCTuY4PIP6c1Sj3j938xIGc1Ikr+YFJKsTw3b6YoL6aDppSJAJCcKMAdh75pkUinBByx6sOgqfzk3EsY92OmKDIdwzGmFG07D1qbMuL0LEW8mPYRkD7yjgCkL5jKkbm9Pb1FQI7ImEOFPbuatBsgmbIwMA+n0pg3YjZsSKyYVQuCG6miPeRkg9epOD+FSCNZELF8KenFVLpPIKICcN3B7UCuiS5LNDt3+YO4zgimR7ArBdwOMADk1GWbcoLKhHT3980kw2DEjZc91/pQXcuGQlSFbIPrxz71CZd52bTvPBI5AquXPlCRWGzOPpUckhVWL9RxxxRckndsxYQg46tUWJAw3xn/e7VApMuQQVHQ84waliYbwYicCk2N6DmOxdo2sCOGz1pPN3kIAd+Og4psnL4/izn0GKZ5SqzMSGGce9NbC5iUt5Z2srcdz1p29ieowfas/czuepHuasxkgHdwB1B6CgLk4UFd6jOOhHIFCBVwcknvzUUkqmA44K8cdKh3/u925Tx+tAXLyTIVcAgA8DPepEkUx5xntx2rOR8xApwCcYPrTnkKYB4x3HAo1C6NLzCA+xhkHOPbFRtJ5ceD/EMg55rOWQZY8hutE87spKjLHjgUDTRqWsvlyqrfMCOeTzR5g34QMBk5DDNULWZ1Y7wMY4PpUiznzs4br680rFxlYvx3XXnBPfHFKJgHC45Pv0qiZVUZAyck+1KJhjcNuG445NS1cfMaccpJwpAPpTJJMS4JBwckDg1UhmAAKkE9CP607eDhQnJPLYJbHvS5WCkjQjeQRAoSASd2ecj2qQSZQl+QBz6is43BVl2hmHrUu7eRhyTnKmlysvc0BPHuVlAIfuDU0TiPcoPJ/DFZKB85LBjn6VbYFojwQw75zmkD0LcgcoX3szNwVAzinRO20K5I7ZycEe/vTIp/lA/jGQf7p/GnRSiOUKy4B5A9T9aYX0LrSJGiqmFboVPBoimOcByoXkIe5qrIx2q0Skbs5YnIpo3GT52GwjPT9aBWTHuXcsFDZ3ZyR0NNjSRSvmM7HOM7cbqmiBBDBlK+nc0eaxYqoO0+p4/+tSK5rDUVuVIfGfulcj8aeR8gCqoI6biDSqe+SW7AHn+Yp0X7xmJPH0zigHIbsOUDEN3OQcg+lIC+GMmMg8Ad6RSd37tWwTjIJGffrUkykHhSMHg0EOS2GRzAj5dzbe2On0qwsu+Mb2UsvJB6fhVNWcAKwP+0RyDSmTy0CqDtJwGfGT+VA2WgxDFlBHAyKmMgBUcsoHOe31qhBcEmRCM+y1PvLAjnJGCcYpkONiVZwrMCdy4IxuonlxgyFScdjgD/GocNG/BHPY9DTJChJVmwR0AOef8Klq4RsnqZOpxfb9TlS1tVaeJFEs/nNFnPIX5eTx61a0dLSRVRrNYJrN2QoJCwVjglge+QRyainspftQntb2S3llAVioBViOmQe/vTtGVVkvIVMjsk58yRyCzttByfzx+FJ6IfLdnJLKrKQf9YCQSec/jToZGEpCOCncMOPyrLhaM7CskgUd2Gc1eRkMjFRtVh95ecmurlZxmgyt5QeMpx6Gq8k4dQWbDqeSKgmJAbYhYZ69qQQNNGWEyBv7tIqJbXc+FMY+bnPeiIBMFhnBPaqsLRmQ+cG4/ukitBn+Xa0vy45I64oKUrD0COqney+1SyM5QRhvlHQ9aotcFFUP8i87TjBP/ANanK6CPdubPUcUmOT7FtZGBG35cdc9KlYRqSxU7cd+9UYnErgkYI7560sryGQfNx3yaDPUdJJtZTwV6BSM1Gd8spKjaCRuxxUZHmudrYAPbg06U8kr8rAdSaEbLYkjQRqcDnPI64qKTYuQwDOeQP7p7VGCZNxU5J9utQlw3yuuCDyaLIm7LBj8ktuUrt6gHNMRgGVVyAR37U1bhw23jgd+OKWR4kiZijebjIIGaLITbZKWCtgkE+4qu7GL5l3ZB3H3zUJcfN8zk9iRjNRgyoww5Knmml2BLuBkcJsXBJOQe9WN5RP4vUEHiq8jEsCVAIGcetRzbjE8auwUnAKnkGnZi5i2ZHUAkA+n1pjSbsccjgio1BCKXJYgYJHQ0Dht5X5iehppWWom9bksciFh820Djp1NPdg+SxOzPAqnLJmQ7hgBhwB1pZrxI13PICvTj09KpwvsLnFe4GSpbbt4/wpYXLRjG48ZBxiqDsXdwpBAIMm3v6UhZt4Kl0B5HbHtS5A9ojV+1Hb97J9xUc1wysEHGTnAFZD3RVgzPtUAE+hx1/WnG9jEyk4K4OGPYgc0ezBVDdWVQBgNlRzUrkkqQOCR7H61z4uAX3BvlPt1q8lyHjPzZk7D0qeQ0U7m1EygNgnK+lONwSu0MRzkGsu3nJjKlz6jFTJMdwxkgcVNrDUtdS27OwynA6lasI2NmM59M96oeYVypGFPc1JFKrNhOSOcUjVS6M0raaRPMJIweD9KtxzoybF2Ke2c8Vkv88oI+UAdDTxM6EGMjaDkn37UrFbmxHM5X5sso+8R0ocidV2nC547AfjVPz9wB3FQeMk/eqxbcE72UYB2e9JrsJ6IuLIhjCygAnqw5Bx2p1qFY7cRnaMA4xn1qKMZHAxxgjGfxqcyFsIoBYcj5eR9KklSHLMpmKqCrAf3uBUzEBSQFG487T1NVlddv70cd1PU++Kl8piqlCWB52jjH4GgXMPQ5YKwO09FHBpXkI42sq9NxIzUW0qzFCSTjJyMU2V96gRAhu4x+uKAuPBhyDvdto5DNjPv6VKskhRmOCuOAO3Peq0KLk53AE+nWpHRD91tqAcg0BuOJThnUnd9OtQ7t8eNpH0Io27WO08H7o+7UoALLkgKTyM5pGl0tSNX8uNtwyzcHnFTQTFQN+V28bc5FMljXJVCNuPyqDDDggvj07UEuVy3JLk58tGbrkAVG+ZY2MQMchUhSV6H1pygHG0Fmxxj+GoJ3ENrLM+WVAWO3qMCmTsZ7WmqsAp1WME9jbL/jUmkW8mnrP503nSSyeYzbNvYDGPwqq0mqSxrOEtIwwDKj72bB9SKtWd01xDMkqiOaFtsgU5BPBGD6YNLQcWcDF5vmBlZHXPA6DNT2qhlbzGZQT1WqMEoidlO5kB6gcVpIw3fK37vAOPWuyxzPQejbXYEqwOCBjn8PSpWXbCPMwJM8Nj+dV3miTYEQg9GbPFS5D5CnPPO41FkIV0OPmIK4654qcEKhDZ6d+agcSRMAyEgdGzkD8qf5m6SNguH9TU27DHhQAN53Eg45qTzUEUag4wOnrTS8jdCuPXbUM7tIQnJI98AUWYXbJ2uDv3GNdn93oaXzVd8srKP4QaiTapBU7iO9KzY27uQeSB1FFwTHSIx5JcZ43DpSGMqnzyHI+tMjeRnzuGz0oaUOCwAHYjNFyuYRQ68hiTjHXrT1dMNlBxgfjVfcCVIcjPcdBS5/eEM3B/ibihajv5E0pIY4XLH07UxxhVCfe6k0SiSI79yk9sNnipUZihbaHXH50NE31KyJlSGJGOlSJHk47erVKGjfbgFeM4PapCVVicA8d6pK+wnLuVrhAAPlyTSRxswygxn04NTgmTkLtPY0rKQgO4FxnrxirSMpT6IgdCqhSFJPtz9aq3lzFAC8kojRRy+eBWT4j8U2WmKVRxNOf4EPIPv7V5nq3iK61Risj4iJzsTgcdKUmlsZyn0Oy1TxtZQM4tR5zgYLLwDWNpHi+W61JUvI1WBvlPfFcWduGHzDPTAqMMInBxn26VEm5qxm2z6CltRd2yy2Jy5UZIOKx5TPGwSZ+Qcc1R+HHilDEtnIuVx16kV2Gq20VyN64J7AVNPEeyajPZmSvexzRCFsHnjGDVaW3GMjOFPbP+cVcltfLbnO8H86jG+MAoxB7gjOB6V3rllrE1WxRSZvvOp44UZzVyK6Ldcq2eD3qpdTOVVSiKFz8yjGappMwbL52g4HtUuCNoVOjOiF07YTcFHsOtT/AGgw7cAnP3SD/OsO3uVL5ZiV6Djt3q0ki7wAdyqOFz2rJxSN4tM247yR40UuAQOAasRTxPCRgicfxZyDWFG+5wWIX+daVsSE3YI9iawubppIvRy8YOc5+bHWraTMoJAIVf1rKL7sdQB1bvVtH4GWBVhnnuRQ0mO9tjWgYyKrsMtnPOM1agnYYR3BI+6XHFZNrKMYcHJ5yBV2SfIC5Lr16ZpcvmDdy9JO4yBsVh1KmrVtMuSnzO+RjjpWVEXMisiEq54+v9KtWYbziqHLdCC1J6E3NUSgFSVUkDkdcGopbjeUw+WzjnkYz6dqrF9rZG/eCQcimMZFkGGjOMHOOTSauSkaAO9RxkYPX1z+VLLzyEAx3PeozcAj5F2YGTz1/Cgyq2VRiq5+UnnilyjuTH5grKDk/wCelPhzvIKb2PUf15pkcUoWRo2VAT1Zf881IrMArZxtPc5pMHJDnSN2dgDxkE5PFNaJdolUgM3r3pz+WqZJyeu0d6QPujGVwfQDoPakTzDSCXGec9aWONSjHuc1LDCmzlHJH97rViONShO3nGOlIOfQrPAAo5ySOCDxVeZAkDGRgVCnf2AHfNXzChycZbgZHTFRmOJGOWIGCcmgXOckP7ISNdmrTQxMMBEuDtHsPQVpaZ9jW3K2BSWAMdzBtx3e56k0kN1p1tHILdLuWF3LgpbsyLnrtOOlaFrcQXcAlswpXoWC4IPoR2NMSmeRwTO33gjJnmQLj8a0I0dW3R5Kkcsed1ZrNCXVZXwRwGQ/KaeJGgZvJ+deBmuyxgpGwsiKMhVHrzzTC3mOeNgHHy96pGXLHB3IDkhlxVxMv+8AXymJA20iuZIcLkKxVYw56gnjH5VbSeMMPOHmYGDg8j8ay9o3nyw2wn71Wml2IDIFUHjI60WDctYVyzYYqem49KZKVyB37HPWq/lvj5XVkPP3sGoo2UzA/MR29qlpl3RpRxAKAh2seozxTQCGOT5i46j+VQJzKv8AGD1I6CppVWNgA24ZyMdvrS5e4cyJYXiIHJX1qB2znapAqwMMuxo9w6kjikBVGCsHJUdAv8jT5Rc6IViVVAC7vX0pzoXYBsKO3PWljfCswGQeNo6inLK77o1OGA+XjpVKJLmMIMZwygZ4Ip4UHIU7Sv5fhSJG5OZD3z+NSzlLVGlmdVPqzDAFUqbZm6lmAQFSF5Ydz3/GnGFFH7yVUfrjrmuW1nx1pNjvS1LXMq/3eh/GuB1/xvfaqGVWMUXZEbFJtR0IlM9K1bxNpulRus9yrSDkRpjmvOPEPjm/1F3SyCwW57J1b8a5OWSWcl2ZmPTJNCo2M4X0qXMjmuI0jyFnkZix5PvT41AUYpcNxjihQf4sVk2Ju7uOVeTimsiuT03VIvB56Usg5G3j3FTcpaiaVevpl8JY93HUZr3fwnqK63p6yuhRsdhXgMqndlc57V2HgzxlPpMkdtPxCDwTU1Ic2pM422PVdR00wlZos5A5BGcis1rbdGWUBR1INdHput2epxAJLG+QOCcE/hVG809TdkROcdSPSuanXnh5K2qFGRyt7CGj+Q4HpjNUpEjACNHnuWzk8V2F1ZjIVgMY78VkXGnFQSM8nHHNe1CrGpHmiXzI5w5EmVRiO5Jxj/GtC3VhH8ijceTg/wA6JbQxL+8IxzgntVTYyjqQR3xVWujaD7GnZOVJJOWPUDjFXklPzAAs2McmsW2nLSMocDP8WOlTIWjnDKW65+tYONjbn6G2Jegxs7enNTxndtLNls8kEVm27bjvf7x+UgnoPWpm+XGGyfYVEtTRSNlJm4GVKAYXjkVMjuVXgLs5yrcms2KVdnHP481a8zJ2tgMRnGc1m1YfOaVvcls78Mh4GRir8EkQII3ZIzjPasZZRsUEKcdzx+FWIrlgnBywHAAHShAaaLHjLycjIU44xUxCssYOMngFR1NZ5unjhDYUHgAHvVhpPO+YudvYA5pNXEXAPKLM6LnA5Bxk96ejMBnB5PGeoHpVOGRXUEMd+45X2/GlVn2tu3ZY8Z7UkmO/c0os4AkkJIPA61Ku7cyuV61SV2UAM2MgAlR1q3HJGAQGOSOfXNBLsSoWOd7KAOh6VKpCrkuQcc4Gc+1VPOYMpdV44HP8xU+cbiHVW6Y6ipauSWEkZsYzx0zgfzqZHk2bnTP15qhulztLE98jFTQsWQBpDtHOTUsC00pZM/Lx1FV54xcW80LHYsqFcr2BGDT4wqIxAUsT1J4qHUozNayxwHEjxsN3QZIwKRLuZkF1qSKLe2/sy78sBN6zFSMDHzKBxVnS4XhFw8rxSzSylpVjGFRsAbR+AHWqVvpQks7aa1txp17bjah4GSOobHVTU2iLcK2oTXlu8LSXBYITkH5VGQe44piSa3PHIZZIYgy4Kn+9yxqZbkvIgWFFcEduK0106aWNwskRh5wQRkfSnwWMgUQmJmB6NjrXp8ljkVQG8wIC0Cxqw5PdhUkDmMkx/MMYweg/CmeRKJBuU7VGM9CKcJJRJIo3emMAVDhfUfOOZo2LMUOOvyn+VRuvmuzRjKr680sYdYioXLscryOPY1ZEUrncYwWxyA/GKOQqMyvEm9CoUlh1IGcVadBEq7kaPcP4u9WVV4l8yEGIHrtbr+FMkhnndZHVpV6fN1FLkJ9qVRzldrY7nNSF1IIAAA71ajtJRtDME2HOCetRT3NpaAmZyzAcqvJNNUxOsh0DNnCckcH3q6ikZKwje3XDYH5Vx9/4wjtkZbSxaU5+8xxiuavvH2tMDGixwqehAp8ltyXVvsepTLHbQbrmSKEernAFYWteL9A0pQRObqbH3YhkD8a8h1TWdUv5Cbq5eQDoxJ/l0rMTec7j1561nKa6ApPZne6x8Rrq4bbYwrAOgYdxXFX2p3d/M0l3cySMeo3HpUO3IAJ4FBTcMfrWTm3uN6kWA5PGPen+UDxmnrGaftPcVNwEVR0BAFOB56fpTwqgc4pemT1FQwGYPUkdPSlXGD0oB4I9aUYwcY60gIm+8cVKeVIFIQPxpy96Q4kTJtBOapyAOxPQ1off+XoM1DKmM+lVGVmNi6Vqlzpt1HNFI5284B6CvTfB3jyO71QQ3Z2h+CxNeTyrhSQKiRzDOkiMQQQetU6anqtzNxPqJwjsrIA0bA4xzWHcQMt1vckRE8dqZ4Svmn0i1Z3XcUHyn1rRvlL2coYFVXofwrj1TvEjZmLdQR3QPlsBzjB4/Gs+5099uPuAjIJ70tncLIZImJVh8wJPSkutUna2E0Sq0SfKyk9676eLUviNYtopGBI3OVY4OCx7fSnqp3ZLMq9s9xT7XWrC+k2OTFJn7r8Afj3q7NaGeOPyD5q55ycDFdMZwlszRNblWFyGDEDA/GrnnZVS33vr1FVWheNjGpXcONoPSjb5RWOZhyfuipcUaqoaSyjcMgkHGCvNaMZR3XD4IHIY4rEiZV3Avj0xwasKyMhXfluoOMk1DL50bUbL/EMj+VWVEYV9rMCB2rGt5t2BIAO7Hv8AlWpE+/5WK/LzkdxUOJUZocJCMbmLg8D2p+9gXXLY4x2/CiTIwfukDOKekkc0ayBsqRjYeM81BSmmSxkHc7YB6Y7mr8M8UhXpgDq3PNZW5WJ4+Xsv0q7EQke4FhnqSM/hQDkXGb7zFAAOnNNjJw2ec9+4qibjpyQAcAGrUT5cNlWfqQ1G4JXL8RBZWABwMcnrVtpA0YG1QR2zWZFcnevBJPQjt61aST5Og5OckUhFguqyA4AJGcdasq4kVSIxtXvVEOnmAs5bdjA7VYUht7b8hffvWQFpS7SBSEUnpzSSFYy5klHAyT2AFMjbAJyozio9QQ3FrcQKdrSRlRz60hFMX87xPMi2y264+WWXa+D0yMYXPvWvbTi6h3MpVwSpjb7ykdQf8a56O4aKK6hlFrE0xLus4bepIwQFA+cemDWtowMNvK7F1MjDajD59oUKCfc4z+NMNz5+huZhDLiRhtY4xWjp2r33kk/aGyoGOBRRXsHiwOl0q7mntGeV9znHOB61vLDHKd8iAtjrRRUM0YW1tDlj5a5pZIkBOFA7UUUkPoaEaIRH8o6elOCgFwAMZoorVbmcypdRIzqCoPFY99awbm/dLwOKKKvoZtnIahbxEOdg4JrmL2GPH3BxRRWMxwZhXKLhhtGM1TCKDwBRRXHUOiO49VHPFIB27UUVijZbDqBRRTGNH3R9aF+6aKKliEoWiikwYtOWiikOI2P75qSQAqaKKT3KZUYAg5FQ2yK11CGUEFhRRWt9GT0PdNEVVt4AowNoOPwrbmdvKljz8mOn4UUVx0zI5HU4Y0t96KFbHUfWsTTCTcBScqx5B780UVHVFozdfhji1t1jUKARXRWU8sTW/luy5HIHQ0UVrReptPobMyq+1nUFiuScUl9GgFuQoz/9aiivZWxJWbmKTPamw9SOxoorGe5oagRQigD+EGrMTELHg9Tj9KKKg0gTxuzyx7iTjj9KieeUS4DkAdBRRUSLLcTszMWOTipd7Y+8cYHH40UVA2WRzKoPTFWY/kDFeD60UU0A+Dm2387s4zmrFoxkZlkO4Yzg0UUgLMMjlxljwOKsWxLspbnOaKKyAkIHmY7ZpzcDI6hgM0UUDQ+7kZWUKxApqcsCfSiigR//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A solitary, tan plaque is present on this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26134=[""].join("\n");
var outline_f25_33_26134=null;
var title_f25_33_26135="Antidepressant medication in adults: Switching and discontinuing medication";
var content_f25_33_26135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antidepressant medication in adults: Switching and discontinuing medication",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/33/26135/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/33/26135/contributors\">",
"     Michael Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/33/26135/contributors\">",
"     Robert J Birnbaum, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/33/26135/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/33/26135/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/33/26135/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/33/26135/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/33/26135/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients fail to respond to a particular antidepressant, or exhibit side effects, and a trial of another antidepressant is indicated, the clinician must be familiar with the pharmacology of the drug that is being discontinued, the potential for drug-drug interactions, and the time to onset of effectiveness of the new medication. Similarly, when antidepressants are being discontinued after a therapeutic course, care must be taken to avoid precipitating an antidepressant withdrawal syndrome. These issues are addressed in this topic. Indications for switching or stopping antidepressants, general information about the treatment of depression and individual medications, and the prognosis of depression are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=see_link\">",
"     \"Unipolar depression in adults: Prognosis and course of illness\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SWITCHING ANTIDEPRESSANT MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several issues to consider when switching a patient from one antidepressant to another, to avoid drug toxicity or re-emergence of depression symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cross-tapering",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many drug switches, cross-tapering is the best technique to assure that the patient's depression is not unmasked from rapid drug withdrawal, while minimizing the risk of drug-drug interactions. In a cross-taper, the dose of the current antidepressant is gradually reduced, over a one to two week period or longer, while the dose of the antidepressant being initiated is gradually increased to therapeutic range over the same time period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Switching between SSRIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is generally the simplest antidepressant switch. Selective serotonin reuptake inhibitors (SSRIs) overlap in their mechanism of action, and the new SSRI will usually prevent discontinuation symptoms that may occur when the first SSRI is stopped. Substituting a new SSRI at the relatively equivalent dose of the former SSRI is typically well-tolerated (",
"    <a class=\"graphic graphic_table graphicRef53560 \" href=\"UTD.htm?3/63/4091\">",
"     table 1",
"    </a>",
"    ), though starting the new SSRI at a lower dose may also be considered since patients occasionally have idiosyncratic side effects to particular SSRIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Switching from SSRI to TCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common method used to switch from an SSRI to a tricyclic antidepressant (TCA) is a cross-taper (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Cross-tapering'",
"    </a>",
"    above). It is important to remember that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    are strong inhibitors of the p450 enzyme 2D6 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    are significantly milder inhibitors). This enzyme is involved in the metabolism of many TCAs and inhibition will cause an increased TCA blood level (in some cases, several-fold higher), which can result in toxicity. Because of this, TCAs should be started at low doses when cross-tapering with an SSRI, particularly with fluoxetine and paroxetine; TCA blood levels can be checked during this period for added safety.",
"   </p>",
"   <p>",
"    Inhibition of p450 2D6 will be present to some degree until the SSRI is completely cleared; most SSRIs are cleared in approximately five days, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    persists in the system for up to five weeks due to its long half-life. Completely tapering off the SSRI prior to starting a TCA can prevent this issue of drug-enzyme interaction, but is often impractical because of the risk of exacerbating the patient's psychiatric condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     SSRI to venlafaxine or duloxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    both have strong serotonergic properties, switching immediately from most SSRIs to the equivalent dose of venlafaxine (",
"    <a class=\"graphic graphic_table graphicRef53560 \" href=\"UTD.htm?3/63/4091\">",
"     table 1",
"    </a>",
"    ) or duloxetine is typically well-tolerated. If starting from a high dose of an SSRI, a cross-taper may be preferable (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Cross-tapering'",
"    </a>",
"    above). However, caution is needed in switching from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , because venlafaxine and duloxetine are metabolized by p450 2D6 (see discussion above) and it is prudent to start them at low doses. Since fluoxetine has a very long half-life, 2D6 inhibition may be present up to five weeks after discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Venlafaxine or duloxetine to antidepressants other than MAOIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    is associated with uncomfortable discontinuation symptoms upon cessation. Switching to an antidepressant that shares some neurotransmitter effects (such as an SSRI) may mitigate these symptoms to a degree, but does not do so consistently. Because of this, we recommend cross-tapering venlafaxine with the new antidepressant over a two to three week period (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Cross-tapering'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Less is known about discontinuation symptoms with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ; since it shares many characteristics with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , it is prudent to also employ this manner of cross-taper when switching to a new antidepressant. Duloxetine is an inhibitor of the liver enzyme p450 2D6, so may increase the blood levels of medications that rely on this enzyme for their metabolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Switching between venlafaxine and duloxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;These medications share many properties. At low doses (less than 150 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    or less than 60 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ), immediately switching from one medication to another is usually well-tolerated. At higher doses, a cross-taper may be preferred (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Cross-tapering'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Switching to or from mirtazapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cross-taper is recommended in switching between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    and SSRIs, TCAs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H3\">",
"     'Cross-tapering'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bupropion to or from antidepressants other than MAOIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    does not have significant serotonergic properties, so would not be expected to mitigate discontinuation symptoms that result from discontinuing medications that are strongly serotonergic. Therefore, when switching from an SSRI, a TCA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    to bupropion, we recommend cross-tapering off the former medication over a one to two week period (two to three weeks for venlafaxine and duloxetine) (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Cross-tapering'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    itself is not frequently associated with discontinuation symptoms. Bupropion can usually be tapered off over the course of one week while initiating a new antidepressant medication at its typical dosing schedule. Bupropion is an inhibitor of the liver enzyme p450 2D6, so may increase the blood levels of medications that rely on this enzyme for their metabolism. Of note, bupropion is also metabolized by the liver enzyme p450 2D6; antidepressants that inhibit p450 2D6, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , may increase the blood level of bupropion, potentially increasing the risk of bupropion-induced seizure. Because of this, it is prudent to avoid prescribing high-dose bupropion concomitantly with paroxetine, fluoxetine, or fluvoxamine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Switching to or from MAOIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the combination of MAOIs and other antidepressants can result in severe toxicity (eg, hypertensive crisis, serotonin syndrome), it is recommended that two weeks elapse between discontinuing an MAOI and starting a different antidepressant.",
"   </p>",
"   <p>",
"    Two weeks should also elapse between discontinuing a TCA, SSRI (other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    and starting an MAOI. Because of fluoxetine's long half-life, five weeks should elapse between discontinuing fluoxetine and starting an MAOI.",
"   </p>",
"   <p>",
"    When switching between MAOIs we recommend that two weeks elapse between discontinuing the first MAOI and starting the second.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DISCONTINUATION OF ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most antidepressants have been associated with adverse effects when abruptly discontinued. Symptoms may be prevented if patients are informed when initiating medication about risks associated with abrupt discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/1\">",
"     1",
"    </a>",
"    ]. While discontinuation symptoms are usually mild and self-limited, this is not always the case and complexity can arise when discontinuation symptoms persist and become difficult to distinguish from the underlying depression.",
"   </p>",
"   <p>",
"    When antidepressants are discontinued, it is common practice to taper them over two to four weeks to minimize symptoms associated with abrupt discontinuation. However, data conflict on the effectiveness of slow medication tapers. A randomized trial with 28 patients compared tapering over three days with tapering over two weeks, and found no difference in discontinuation and depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/2\">",
"     2",
"    </a>",
"    ]. By contrast, an observational study of 224 patients found that the median time to recurrence of depression in euthymic patients who discontinued their antidepressant over one to seven days was significantly shorter compared with patients who discontinued their antidepressant over 14 or more days (3.2 versus 7.6 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/3\">",
"     3",
"    </a>",
"    ]. Both studies found that antidepressants with a short half-life (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) were associated with significantly more discontinuation and depressive symptoms. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Selective serotonin reuptake inhibitors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Venlafaxine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A constellation of discontinuation effects, sometimes referred to as a \"discontinuation syndrome,\" has been best characterized with abrupt cessation of SSRIs. The constellation of symptoms, which typically occurs within days of abrupt cessation of an SSRI, may include dizziness, nausea, fatigue, muscle aches, chills, anxiety, and irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. Although these symptoms are not dangerous and usually dissipate over one to two weeks, they can be quite distressing and uncomfortable.",
"   </p>",
"   <p>",
"    While discontinuation symptoms can occur with any SSRI, different SSRIs have different likelihoods of producing symptoms with abrupt discontinuation, perhaps related to differences in half-life; symptoms are mild with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (long half-life) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/6\">",
"     6",
"    </a>",
"    ] and can be particularly severe with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    . Blinded trials have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      cessation produces less severe symptoms than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/7-10\">",
"       7-10",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"      cessation produces less severe symptoms than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      cessation produced only mild symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/11\">",
"       11",
"      </a>",
"      ], and symptoms also appear to be less severe than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    causes the least discontinuation symptoms, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    causes the most discontinuation symptoms. A study of physician-initiated reports of adverse drug reactions included 430 cases of withdrawal reactions from paroxetine; analysis of 71 patients who were not treated for the withdrawal syndrome from paroxetine found that the mean time to recovery was 11 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical experience suggests that discontinuation symptoms associated with SSRI withdrawal can be reduced by a slow tapering of the drug. An observational study found that patients who tapered their medication reported fewer adverse effects than patients who stopped medication abruptly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/5\">",
"     5",
"    </a>",
"    ]. However, a small trial (n = 28) found no difference in symptoms between patients randomly assigned to taper their SSRI over 3 days or over 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/2\">",
"     2",
"    </a>",
"    ]. These results need to be confirmed in a larger trial.",
"   </p>",
"   <p>",
"    Patients who have difficulty tapering off of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    may benefit from being switched to an equivalent dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef53560 \" href=\"UTD.htm?3/63/4091\">",
"     table 1",
"    </a>",
"    ); the fluoxetine can then be tapered off, typically without discontinuation effects.",
"   </p>",
"   <p>",
"    In addition, patients who suffer a discontinuation syndrome after an SSRI has been stopped can be acutely treated by starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    10 to 20 mg per day. Once the withdrawal symptoms have abated and the patient has been stabilized on fluoxetine 10 mg per day for one to two weeks, the drug can be discontinued. For patients who have difficulty discontinuing fluoxetine 10 mg per day, a liquid formulation is available for administering a dose less than 10 mg per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Venlafaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abrupt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    commonly causes discontinuation symptoms, including dizziness, flu-like symptoms, and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/4,13,14\">",
"     4,13,14",
"    </a>",
"    ]. These symptoms may be more severe than those produced by SSRI discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Heterocyclics and MAOIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the distressing, yet typically benign discontinuation symptoms described above, abrupt discontinuation of heterocyclic antidepressants and MAOIs can cause severe and potentially dangerous discontinuation syndromes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abrupt discontinuation of heterocyclic antidepressants can cause irritability, agitation, sleep disturbance, flu-like symptoms and, rarely, cardiac arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abrupt cessation of MAOIs can cause delirium, agitation, myoclonic jerks, and insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other antidepressants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There have been anecdotal reports of discontinuation effects from abrupt cessation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , but these effects are not well characterized [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In controlled trials, discontinuation symptoms with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      were more common than with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26135/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Discontinuation symptoms from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      are uncommon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educating patients about discontinuation symptoms can help prevent them from abruptly stopping antidepressants and may help reduce anxiety should adverse discontinuation effects occur.",
"   </p>",
"   <p>",
"    When stopping antidepressant treatment, antidepressants should be tapered; the antidepressant dose should be reduced by 25 percent per week so as to minimize the occurrence of discontinuation side effects. Among SSRIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    probably causes the least discontinuation symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"       \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95738192\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95738200\">",
"    <span class=\"h2\">",
"     Switching between antidepressants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For many drug switches, cross-tapering is the best technique. In a cross-taper, the dose of the current antidepressant is gradually reduced over a one to two week period or longer, while the dose of the new antidepressant is gradually increased to therapeutic range over the same time period. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cross-tapering'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To switch between selective serotonin reuptake inhibitors (SSRIs), we generally substitute the new SSRI at the relatively equivalent dose of the discontinued SSRI (",
"      <a class=\"graphic graphic_table graphicRef53560 \" href=\"UTD.htm?3/63/4091\">",
"       table 1",
"      </a>",
"      ). A reasonable alternative is to start the new SSRI at a lower dose because patients may have idiosyncratic side effects to particular SSRIs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Switching between SSRIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To switch from an SSRI to a tricyclic antidepressant (TCA), we generally use cross-tapering. The TCA is started at a low dose to avoid toxicity that can result from the SSRI inhibiting the hepatic enzyme that metabolizes TCAs. Serum TCA concentrations can be checked during this period for added safety. Inhibition of the hepatic enzyme occurs to some degree until the SSRI is completely cleared; most SSRIs are cleared in approximately five days, but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      persists in the system for up to five weeks due to its long half-life. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Switching from SSRI to TCA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To switch from an SSRI to the strongly serotonergic drugs",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      , we generally switch immediately to the equivalent dose of venlafaxine (",
"      <a class=\"graphic graphic_table graphicRef53560 \" href=\"UTD.htm?3/63/4091\">",
"       table 1",
"      </a>",
"      ) or duloxetine. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'SSRI to venlafaxine or duloxetine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To switch from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      to antidepressants other than MAOIs, we generally use cross-tapering over a two to three week period. Duloxetine inhibits the liver enzyme that metabolizes some antidepressants and may thus increase their serum concentrations. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Venlafaxine or duloxetine to antidepressants other than MAOIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To switch between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      at low doses (&lt;150 mg of venlafaxine and &lt;60 mg of duloxetine), we generally switch immediately, and at higher doses use cross-tapering. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Switching between venlafaxine and duloxetine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To switch between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      and SSRIs, TCAs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      , we generally use cross-tapering. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Switching to or from mirtazapine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To switch between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      and antidepressants other than MAOIs, we generally use cross-tapering over a one to two week period (two to three weeks for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ). Bupropion inhibits the liver enzyme that metabolizes some antidepressants and may thus increase their serum concentrations. In addition, bupropion is metabolized by the same enzyme, and antidepressants that inhibit it, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      , may increase the serum concentration of bupropion, potentially increasing the risk of bupropion-induced seizure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bupropion to or from antidepressants other than MAOIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of monoamine oxidase inhibitors (MAOIs) and other antidepressants can result in severe toxicity (eg, hypertensive crisis or serotonin syndrome). Thus, we wait two weeks between discontinuing an MAOI and starting a different antidepressant. In addition, two weeks should also elapse between discontinuing a TCA, SSRI (other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      and starting an MAOI. Due to the long half-life of fluoxetine, five weeks should elapse between discontinuing fluoxetine and starting an MAOI. When switching between MAOIs, we allow two weeks to elapse between discontinuing the first MAOI and starting the second. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Switching to or from MAOIs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95738720\">",
"    <span class=\"h2\">",
"     Discontinuation of antidepressants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most antidepressants have been associated with adverse effects when abruptly discontinued. Educating patients about discontinuation symptoms can help prevent them from abruptly stopping antidepressants and reduce anxiety should adverse discontinuation effects occur. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Discontinuation of antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When antidepressants are discontinued, we typically taper them over two to four weeks to minimize symptoms associated with abrupt discontinuation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/1\">",
"      Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician 2006; 74:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/2\">",
"      Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008; 22:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/3\">",
"      Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/4\">",
"      Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997; 58 Suppl 7:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/5\">",
"      van Geffen EC, Hugtenburg JG, Heerdink ER, et al. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005; 61:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/6\">",
"      Zajecka J, Fawcett J, Amsterdam J, et al. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 1998; 18:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/7\">",
"      Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/8\">",
"      Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/9\">",
"      Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000; 176:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/10\">",
"      Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000; 15:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/11\">",
"      Markowitz JS, DeVane CL, Liston HL, Montgomery SA. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000; 15:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/12\">",
"      Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/13\">",
"      Fava M, Mulroy R, Alpert J, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/14\">",
"      Parker G, Blennerhassett J. Withdrawal reactions associated with venlafaxine. Aust N Z J Psychiatry 1998; 32:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/15\">",
"      Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 1994; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/16\">",
"      Lejoyeux M, Ad&egrave;s J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997; 58 Suppl 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/17\">",
"      Dilsaver SC. Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatr Scand 1988; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/18\">",
"      Rajagopalan M, Little J. Discontinuation symptoms with nefazodone. Aust N Z J Psychiatry 1999; 33:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26135/abstract/19\">",
"      Klesmer J, Sarcevic A, Fomari V. Panic attacks during discontinuation of mirtazepine. Can J Psychiatry 2000; 45:570.",
"     </a>",
"    </li>",
"    <li>",
"     pi.lilly.com/us/cymbalta-pi.pdf (Accessed 8/5/04).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1716 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26135=[""].join("\n");
var outline_f25_33_26135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95738192\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SWITCHING ANTIDEPRESSANT MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cross-tapering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Switching between SSRIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Switching from SSRI to TCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SSRI to venlafaxine or duloxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Venlafaxine or duloxetine to antidepressants other than MAOIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Switching between venlafaxine and duloxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Switching to or from mirtazapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bupropion to or from antidepressants other than MAOIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Switching to or from MAOIs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DISCONTINUATION OF ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Venlafaxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Heterocyclics and MAOIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95738192\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95738200\">",
"      Switching between antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95738720\">",
"      Discontinuation of antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1716\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1716|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/63/4091\" title=\"table 1\">",
"      Dose equivalents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_33_26136="Fluticasone and salmeterol: Drug information";
var content_f25_33_26136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluticasone and salmeterol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8454?source=see_link\">",
"    see \"Fluticasone and salmeterol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/53/23384?source=see_link\">",
"    see \"Fluticasone and salmeterol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advair Diskus&reg;;",
"     </li>",
"     <li>",
"      Advair&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advair Diskus&reg;;",
"     </li>",
"     <li>",
"      Advair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F173452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist, Long-Acting",
"     </li>",
"     <li>",
"      Corticosteroid, Inhalant (Oral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F173436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use to transfer patients from systemic corticosteroid therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      COPD:",
"     </b>",
"     Oral Inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair Diskus&reg;: Fluticasone 250 mcg/salmeterol 50 mcg twice daily, 12 hours apart.",
"     <b>",
"      Note:",
"     </b>",
"     This is the maximum dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair Diskus&reg; [Canadian labeling; not in approved U.S. labeling]: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     fluticasone 500 mcg/salmeterol 50 mcg twice daily, 12 hours apart.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum dose: Fluticasone 500 mcg/salmeterol 50 mcg per inhalation (2 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma (maintenance):",
"     </b>",
"     Oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair Diskus&reg;: One inhalation twice daily, morning and evening, 12 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum dose: Fluticasone 500 mcg/salmeterol 50 mcg per inhalation (2 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair&reg; HFA: Two inhalations twice daily, morning and evening, 12 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum dose: Fluticasone 230 mcg/salmeterol 21 mcg per inhalation  (4 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair&reg; 125 or Advair&reg; 250 [Canadian labeling; not in approved U.S. labeling]: Two inhalations twice daily, morning and evening, 12 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum dose: Fluticasone 250 mcg/salmeterol 25 mcg per inhalation (4 inhalations/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose prescribed should be based upon previous dose of inhaled-steroid asthma therapy. Dose should be increased after 2 weeks if adequate response is not achieved. Patients should be titrated to lowest effective dose once stable. Each suggestion below specifies the product strength to use; remember to",
"     <b>",
"      use 1 inhalation for Diskus&reg; and 2 inhalations for HFA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Patients not currently on inhaled corticosteroids:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Advair Diskus&reg;: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     fluticasone 250 mcg/salmeterol 50 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"     <b>",
"      or",
"     </b>",
"     fluticasone 115 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients currently using inhaled beclomethasone dipropionate:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;160 mcg/day: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     320 mcg/day: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 115 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     640 mcg/day: Fluticasone 500 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 230 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients currently using inhaled budesonide:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;400 mcg/day: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     800-1200 mcg/day: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 115 mcg/salmeterol 21mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1600 mcg/day: Fluticasone 500 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 230 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients currently using inhaled flunisolide CFC aerosol:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;1000 mcg/day: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1250-2000 mcg/day: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 115 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients currently using inhaled flunisolide HFA inhalation aerosol:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;320 mcg/day: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     640 mcg/day: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 115 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients currently using inhaled fluticasone HFA aerosol:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;176 mcg/day: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     440 mcg/day: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 115 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     660-880 mcg/day: Fluticasone 500 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 230 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients currently using inhaled fluticasone propionate powder:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;200 mcg/day: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500 mcg/day: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 115 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1000 mcg/day: Fluticasone 500 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 230 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients currently using inhaled mometasone furoate powder:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     220 mcg/day: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     440 mcg/day: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 115 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     880 mcg/day: Fluticasone 500 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 230 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients currently using inhaled triamcinolone acetonide:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;1000 mcg/day: Fluticasone 100 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 45 mcg/salmeterol 21 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1100-1600 mcg/day: Fluticasone 250 mcg/salmeterol 50 mcg",
"     <b>",
"      or",
"     </b>",
"     Advair&reg; HFA: Fluticasone 115 mcg/salmeterol 21 mcg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F173446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/53/23384?source=see_link\">",
"      see \"Fluticasone and salmeterol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Asthma: Oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 4-11 years: Advair Diskus&reg;: Fluticasone 100 mcg/salmeterol 50 mcg twice daily, 12 hours apart.",
"     <b>",
"      Note:",
"     </b>",
"     This is the maximum dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F173437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, fluticasone and salmeterol are predominately eliminated by hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F173438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required; manufacturer suggests close monitoring of patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair&reg; HFA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     45/21: Fluticasone propionate 45 mcg and salmeterol 21 mcg per inhalation (8 g) [chlorofluorocarbon free; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     45/21: Fluticasone propionate 45 mcg and salmeterol 21 mcg per inhalation (12 g) [chlorofluorocarbon free; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     115/21: Fluticasone propionate 115 mcg and salmeterol 21 mcg per inhalation (8 g) [chlorofluorocarbon free; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     115/21: Fluticasone propionate 115 mcg and salmeterol 21 mcg per inhalation (12 g) [chlorofluorocarbon free; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     230/21: Fluticasone propionate 230 mcg and salmeterol 21 mcg per inhalation (8 g) [chlorofluorocarbon free; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     230/21: Fluticasone propionate 230 mcg and salmeterol 21 mcg per inhalation (12 g) [chlorofluorocarbon free; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair Diskus&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     100/50: Fluticasone propionate 100 mcg and salmeterol 50 mcg (14s, 28s [DSC], 60s) [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250/50: Fluticasone propionate 250 mcg and salmeterol 50 mcg (14s [DSC], 60s) [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500/50: Fluticasone propionate 500 mcg and salmeterol 50 mcg (14s [DSC], 60s) [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F6103145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair&reg;;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     125/25: Fluticasone propionate 125 mcg and salmeterol 25 mcg per inhalation (12 g) [120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250/25: Fluticasone propionate 250 mcg and salmeterol 25 mcg per inhalation (12 g) [120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Advair Diskus&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111326.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111326.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Advair&reg; HFA:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111333.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111333.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F173417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Advair Diskus&reg;: After removing from box and foil pouch, write the &ldquo;Pouch opened&rdquo; and &ldquo;Use by&rdquo; dates on the label on top of the Diskus&reg;.  The &ldquo;Use by&rdquo; date is 1 month from date of opening the pouch. Every time the lever is pushed back, a dose is ready to be inhaled. Do not close or tilt the Diskus&reg; after the lever is pushed back. Do not play with the lever or move the lever more than once.  The dose indicator tells you how many doses are left. When the numbers 5 to 0 appear in red, only a few doses remain. Discard device 1 month after you remove it from the foil pouch or when the dose counter reads &ldquo;0&rdquo; (whichever comes first). Rinse mouth with water after use and spit to reduce risk of oral candidiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Advair&reg; HFA: Shake well for 5 seconds before each spray. Prime with 4 test sprays (into air and away from face) before using for the first time. If canister is dropped or not used for &gt;4 weeks, prime with 2 sprays. Patient should contact pharmacy for refill when the dose counter reads &ldquo;020&rdquo;. Discard device when the dose counter reads &ldquo;000&rdquo;. Do not spray in eyes. Rinse mouth with water after use and spit to reduce risk of oral candidiasis.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F173416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment of asthma; maintenance treatment of COPD",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Advair&reg; may be confused with Adcirca&reg;, Advicor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F173450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported in patients with asthma; also see individual agents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (12% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (16% to 27%), pharyngitis (9% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menstruation symptoms (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (3% to 6%), diarrhea (2% to 4%), pain/discomfort (1% to 4%), oral candidiasis (1% to 4%), gastrointestinal infections (including viral, &le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (2% to 7%), muscle pain (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Throat irritation (7% to 9%), bronchitis (2% to 8%), upper respiratory tract inflammation (4% to 7%), lower respiratory tract infections/pneumonia (1% to 7%; COPD diagnosis and age &gt;65 years increase risk), cough (3% to 6%), sinusitis (4% to 5%), hoarseness/dysphonia (1% to 5%), viral respiratory tract infection (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 3%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, chest symptoms, fluid retention, MI, palpitation, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Compressed nerve syndromes, hypnagogic effects, migraine, pain, sleep disorders, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis, dermatosis, eczema, hives, skin flakiness, urticaria, viral skin infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dental discomfort/pain, gastrointestinal infection, hemorrhoids, oral discomfort/pain, oral erythema/rash, oral ulcerations, unusual taste, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Contusions/hematomas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Abnormal liver function tests",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, articular rheumatism, bone/cartilage disorders, bone pain, cramps, fractures, muscle injuries (&le;3%), muscle spasm, muscle stiffness, tightness/rigidity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis, edema, eye redness, keratitis, xerophthalmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Blood in nasal mucosa, congestion, ear/nose/throat infection, epistaxis, laryngitis, lower respiratory hemorrhage, nasal irritation, rhinitis, rhinorrhea/postnasal drip, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergies/allergic reactions, bacterial infection, burns, candidiasis (&le;3%), diaphoresis, sweat/sebum disorders, viral infection, wounds and lacerations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Asthma exacerbation (serious and some fatal), abdominal pain, agitation, aggression, anaphylactic reaction (some in patients with severe milk allergy [Diskus&reg;]), angioedema, aphonia, atrial fibrillation, bronchospasm, cataracts, chest congestion, chest tightness, choking, contact dermatitis, Cushing syndrome, Cushingoid features, depression, dysmenorrhea, dyspepsia, dyspnea, earache, ecchymoses, edema (facial, oropharyngeal), eosinophilic conditions, glaucoma, growth velocity reduction in children/adolescents, hyperactivity, hypercorticism, hyperglycemia, hypersensitivity reaction (immediate and delayed), hypertension, hypokalemia, hypothyroidism, influenza, intraocular pressure increased, irritability, laryngeal spasm/irritation, irregular menstruation, myositis, osteoporosis, pallor, paresthesia, paradoxical tracheitis, paranasal sinus pain, photodermatitis, PID, rash, restlessness, stridor, supraventricular tachycardia, syncope, vaginal candidiasis, vaginitis, vulvovaginitis, rare cases of vasculitis (Churg-Strauss syndrome), ventricular tachycardia, wheezing, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F173420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluticasone, salmeterol, or any component of the formulation; status asthmaticus; acute episodes of asthma or COPD; severe hypersensitivity to milk proteins (Advair Diskus&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F173404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: Fluticasone may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Concurrent use of ritonavir (and potentially other strong inhibitors of CYP3A4) may increase fluticasone levels and effects on HPA suppression. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Do not use this product to transfer patients from oral corticosteroid therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma-related deaths:",
"     <b>",
"      [U.S. Boxed Warning]: Long-acting beta",
"      <sub>",
"       2",
"      </sub>",
"      -agonists (LABAs), such as salmeterol,  increase the risk of asthma-related deaths; fluticasone and salmeterol should only be used in patients not adequately controlled on a long-term asthma control medication (ie, inhaled corticosteroid) or whose disease severity requires initiation of two maintenance therapies.",
"     </b>",
"     In a large, randomized, placebo-controlled U.S. clinical trial (SMART, 2006), salmeterol was associated with an increase in asthma-related deaths (when added to usual asthma therapy); risk is considered a class effect among all LABAs. Data are not available to determine if the addition of an inhaled corticosteroid lessens this increased risk of death associated with LABA use. Assess patients at regular intervals once asthma control is maintained on combination therapy to determine if step-down therapy is appropriate (without loss of asthma control), and the patient can be maintained on an inhaled corticosteroid only. LABAs are not appropriate in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone density: Long-term use may affect bone mineral density in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox or measles should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment). With oral inhalation, local yeast infections (eg, oral pharyngeal candidiasis) may occur; patient should rinse mouth and spit after each use to reduce incidence. Lower respiratory tract infections, including pneumonia, have been reported in patients with COPD using the oral inhalation with an even higher incidence in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lower respiratory infections: Pneumonia and other lower respiratory tract infections have been reported in patients with COPD following the use of inhaled corticosteroids; monitor COPD patients closely since pneumonia symptoms may overlap symptoms of exacerbations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral candidiasis: Infections with",
"     <i>",
"      Candida albicans",
"     </i>",
"     in the mouth and throat (thrush) have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric manifestations: Corticosteroid use may cause psychiatric manifestations, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Upper airway symptoms: There have been reports of laryngeal spasm, irritation, and swelling (stridor, choking) with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasculitis: Rare cases of vasculitis (Churg-Strauss syndrome) have been reported with fluticasone use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute bronchospasm. Short-acting beta2-agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do",
"     <b>",
"      not",
"     </b>",
"     initiate in patients with significantly worsening or acutely deteriorating asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, hypertension, or HF); beta-agonists may cause elevation in blood pressure, heart rate, and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; COPD: Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute episodes of COPD. Do",
"     <b>",
"      not",
"     </b>",
"     initiate in patients with significantly worsening or acutely deteriorating COPD. Data are not available to determine if LABA use increases the risk of death in patients with COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged fluticasone use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in patients with hyperthyroidism and decreases in hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients.",
"     </b>",
"     Orally-inhaled and intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled and intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose:  Powder for oral inhalation (Advair Diskus&reg;) contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients must be instructed to use short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist (eg, albuterol) for acute asthmatic or COPD symptoms and to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use of inhaled short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist may indicate deterioration of asthma, and medical evaluation must not be delayed. Therapy should not be used more than twice daily; do not use with other long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F173447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F173424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F173441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fluticasone: Excretion in breast milk unknown/use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Salmeterol: Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F173425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Advair Diskus&reg; powder for oral inhalation contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F173423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Advair HFA Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45-21 mcg/ACT (8 g): $168.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     115-21 mcg/ACT (8 g): $168.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     230-21 mcg/ACT (8 g): $249.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (Advair Diskus Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-50 mcg/dose (14): $120.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-50 mcg/dose (14): $120.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-50 mcg/dose (14): $195.78",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F173412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation. Monitor for increased use of short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist inhalers; may be marker of a deteriorating asthma condition. The growth of pediatric patients receiving inhaled corticosteroids should be monitored routinely (eg, via stadiometry).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F173426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aeronid (PE);",
"     </li>",
"     <li>",
"      Fluamar (CO);",
"     </li>",
"     <li>",
"      Salmeflo (PH);",
"     </li>",
"     <li>",
"      Seretaide (PT);",
"     </li>",
"     <li>",
"      Seretide (AR, AT, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CN, CO, CR, DK, DO, EC, EE, ES, FI, FR, GB, GT, GY, HK, HN, ID, IE, IL, IN, IT, JM, KP, MX, MY, NI, NL, NZ, PA, PE, PH, PL, PY, SE, SG, SR, SV, TH, TT, TW, VE);",
"     </li>",
"     <li>",
"      Seretide Accuhaler (AU);",
"     </li>",
"     <li>",
"      Serflu (UY);",
"     </li>",
"     <li>",
"      Seroflo (HK);",
"     </li>",
"     <li>",
"      Viani (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F173403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination of fluticasone (corticosteroid) and salmeterol (long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist) designed to improve pulmonary function and control over what is produced by either agent when used alone. Because fluticasone and salmeterol act locally in the lung, plasma levels do not predict therapeutic effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fluticasone: The mechanism of action for all topical corticosteroids is believed to be a combination of three important properties: Anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions. Fluticasone has extremely potent vasoconstrictive and anti-inflammatory activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Salmeterol: Relaxes bronchial smooth muscle by selective action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with little effect on heart rate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F173419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):1-157. Available at file://content.onlinejacc.org/cgi/reprint/50/7/e1",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/33/26136/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bateman ED, Boushey HA, Bousquet J, et al, &ldquo;Can Guideline-Defined Asthma Control Be Achieved? The Gaining Optimal Asthma Control Study,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2004, 170(8):836-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/33/26136/abstract-text/15256389/pubmed\" id=\"15256389\" target=\"_blank\">",
"        15256389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castle W, Fuller R, Hall J, et al, &ldquo;Serevent Nationwide Surveillance Study: Comparison of Salmeterol With Salbutamol in Asthmatic Patients Who Require Regular Bronchodilator Treatment,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1993, 306(6884):1034-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/33/26136/abstract-text/8098238/pubmed\" id=\"8098238\" target=\"_blank\">",
"        8098238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson HS, Weiss ST, Bleecker ER, et al, &ldquo;The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2006, 129(1):15-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/33/26136/abstract-text/16424409/pubmed\" id=\"16424409\" target=\"_blank\">",
"        16424409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8730 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26136=[""].join("\n");
var outline_f25_33_26136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708807\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173432\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173433\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173452\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173436\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173446\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173437\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896264\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173438\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173414\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6103145\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173400\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874505\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173417\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173416\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173461\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173450\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173420\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173404\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173447\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173408\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173410\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173424\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173441\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173425\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173423\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173412\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173426\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173403\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173419\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8730\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8730|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8454?source=related_link\">",
"      Fluticasone and salmeterol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/53/23384?source=related_link\">",
"      Fluticasone and salmeterol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_33_26137="Cross section of the leg and forearm compartments";
var content_f25_33_26137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Cross section of the leg and forearm compartments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These diagrams show the compartments of the leg (A) and forearm (B), including all major nerves and vascular structures. Note how inaccessible the leg's deep posterior compartment is to direct palpation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harwood-Nuss A, MD, FACEP, Wolfson AB, MD, FACEP, FACP, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26137=[""].join("\n");
var outline_f25_33_26137=null;
var title_f25_33_26138="Mild cognitive impairment: Prognosis and treatment";
var content_f25_33_26138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mild cognitive impairment: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/33/26138/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/33/26138/contributors\">",
"     Eric M McDade, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/33/26138/contributors\">",
"     Ronald C Petersen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/33/26138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/33/26138/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/33/26138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/33/26138/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/33/26138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild cognitive impairment (MCI) is an intermediate state between normal cognition and dementia. While specific changes in cognition are frequently observed in normal aging, there is increasing evidence that some forms of cognitive impairment are recognizable as an early manifestation of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/1\">",
"     1",
"    </a>",
"    ]. The utility of this paradigm centers around the recognition that dementia is not a dichotomous state. Our understanding of transitional states between normal cognition and dementia will improve the understanding of cognitive decline, facilitate early diagnosis, and ultimately benefit patients.",
"   </p>",
"   <p>",
"    This topic will review the prognosis and treatment of MCI. The epidemiology, pathology, and clinical assessment of MCI and topics related to dementia, including diagnosis, treatment, risk factors, and prevention of dementia, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link\">",
"     \"Prevention of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGRESSION TO DEMENTIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally accepted that elderly individuals with mild cognitive impairment (MCI) are at increased risk of developing Alzheimer disease (AD). In a prospective study of 798 older Catholic clergy without dementia, participants were categorized at baseline as having MCI (n = 211) or no cognitive impairment (n = 587) and were followed for an average of 4.5 years with cognitive tests [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/1\">",
"     1",
"    </a>",
"    ]. The group with MCI developed AD at a rate 3.1 (CI 2.1-4.5) times higher than the group with no cognitive impairment. Another study found that MCI was associated with a 2.8-fold increased risk of AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies have agreed that MCI is an important predictor of progression to AD. In one retrospective study, a diagnosis of age-associated cognitive decline was a better predictor of progression to AD than MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/3\">",
"     3",
"    </a>",
"    ]. One criticism of this study is that the MCI criteria were applied retrospectively to neuropsychological test scores [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link&amp;anchor=H2#H2\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In various studies, a substantial percentage (11 to 40 percent) of patients with MCI improve, even to normal, over a one to three-year follow-up time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/3,5-9\">",
"     3,5-9",
"    </a>",
"    ]. This finding emphasizes the clinical heterogeneity of MCI. While one study reported that patients with MCI who improved at follow-up had a similar risk of dementia as those who were never impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/7\">",
"     7",
"    </a>",
"    ], other studies report that patients with MCI who improve remain at substantially elevated risk of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Part of the variability between studies is due to the different populations studied, for example patients referred to memory clinics versus epidemiologic cohorts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;When counseling patients diagnosed with MCI that is suspected to be of neurodegenerative origin, we estimate the risk of progression to dementia to be 10 percent per year.",
"   </p>",
"   <p>",
"    The overall incidence rate of dementia in the general elderly population is estimated at 1 to 3 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]. In contrast, reported annual rates of progression from MCI to dementia have ranged from 5 to 16 percent, with lower rates of progression observed in population-based studies and higher rates in clinical centers and some treatment trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/2,5-7,11-21\">",
"     2,5-7,11-21",
"    </a>",
"    ]. Rates of conversion also vary according to the duration of follow-up; one analysis compared longer duration (&gt;5 years) to shorter duration studies and found lower rates with longer durations of follow-up, suggesting that the risk of conversion decreases over time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/22\">",
"     22",
"    </a>",
"    ]. In this study, the cumulative incidence was 33 percent. Typically, patients convert within a period of two to three years; however, longer intervals of up to eight years have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the heterogeneity of outcomes among individuals with MCI, many studies have investigated factors that might identify those with MCI who will develop dementia. Combinations of risk factors may be more predictive than individual risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/24\">",
"     24",
"    </a>",
"    ]. Risk factors for dementia in the general population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies suggest that socioeconomic variables may be predictors. Gender and education level are not predictors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/21,25\">",
"     21,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outside of the research setting, no test or clinical feature has a well defined role in predicting future dementia in patients with MCI; these are not recommended in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is a primary predictor of progression of MCI to AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/5,18,26-30\">",
"     5,18,26-30",
"    </a>",
"    ]. With every year of age increase, MCI is slightly more likely to convert to AD. MCI is relatively unlikely to represent a predementia condition in patients less than 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/18\">",
"     18",
"    </a>",
"    ], unless there is a family history of early onset dementia associated with an autosomal dominant mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Neuropsychological testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of observational studies suggest that neuropsychological testing is helpful in defining individuals with MCI who are at risk for dementia. Patients who meet MCI criteria according to neuropsychological test performance have a higher rate of conversion to dementia than to those who meet MCI criteria according to the Clinical Dementia Rating scale (",
"    <a class=\"graphic graphic_table graphicRef53706 \" href=\"UTD.htm?0/0/2\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More severely affected patients (with greater deficits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a broader range of deficits) have been shown to be at greater risk for dementia than those who are less affected, according to prospective cohort studies of patients with MCI or \"cognitive impairment, no dementia\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/7,32-38\">",
"     7,32-38",
"    </a>",
"    ]. Deficits that include a primary or prominent amnestic component as well as those that lead to impairment in activities of daily living are also felt to identify patients at higher risk of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/39\">",
"     39",
"    </a>",
"    ]. However, patients with subjective memory complaints who appear unimpaired on neuropsychological testing appear to be at higher risk of cognitive decline and dementia than patients without such complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of specific test measures, such as short delayed verbal recall, visual recognition memory, and other cued memory tasks, as well as measures of instrumental activities of daily living, have also been found to have high predictive value for dementia in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/24,28,33,44-52\">",
"     24,28,33,44-52",
"    </a>",
"    ]. However, these have not been independently and prospectively validated in a manner that allows application to individual cases.",
"   </p>",
"   <p>",
"    Follow-up neuropsychological testing may provide more helpful information regarding prognosis, in that intraindividual change in cognitive function is more sensitive than comparison with group norms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/53\">",
"     53",
"    </a>",
"    ]. In one cohort study, acceleration of cognitive decline occurred approximately three years prior to the diagnosis of AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/32\">",
"     32",
"    </a>",
"    ]. Educational level was an important modulator of test performance and rate of decline. These findings have been corroborated in other cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/34,36,54,55\">",
"     34,36,54,55",
"    </a>",
"    ]. However, the sensitivity and specificity of specific patterns of decline have not been rigorously evaluated. Practice effects, which can lead to test score improvement in normal elderly adults even after an interval of one to two years, may decrease the sensitivity of neuropsychological test decline as a predictor of AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Psychological features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychiatric symptoms are prevalent in individuals with MCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link&amp;anchor=H14#H14\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Neuropsychiatric symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether the presence of such features is predictive of conversion to dementia is uncertain. Studies with different designs, follow-up periods, and inclusion of nonamnestic types of MCI have found increased [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/57-60\">",
"     57-60",
"    </a>",
"    ], decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], or no change in the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/63\">",
"     63",
"    </a>",
"    ] of dementia when MCI is associated with depression. Similarly, studies have had mixed results regarding the predictive value of associated apathy and anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     ApoE epsilon 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apolipoprotein E (APOE) epsilon 4 (&epsilon;4) genotype has been associated with the risk of MCI and AD in the general population but has had mixed association with conversion to AD among individuals with MCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32089?source=see_link&amp;anchor=H899448#H899448\">",
"     \"Genetics of Alzheimer disease\", section on 'Apolipoprotein E'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link&amp;anchor=H10#H10\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies have found that APOE &epsilon;4 is a strong risk factor for conversion from MCI to AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/15,29,33,64-67\">",
"     15,29,33,64-67",
"    </a>",
"    ], but others have found only a marginal or even no association [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/25,26,28,68-70\">",
"     25,26,28,68-70",
"    </a>",
"    ]. A meta-analysis of 35 prospective cohort studies found a moderate association of APOE &epsilon;4 and progression to AD (OR = 2.3), but low sensitivity (0.53) and positive predictive value (0.57 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/71\">",
"     71",
"    </a>",
"    ]). At this time, testing of APOE genetic status is not recommended in MCI patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7911102\">",
"    <span class=\"h3\">",
"     Vascular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the impact of vascular risk factors on the conversion of MCI to dementia have had variable results. In one study of 837 patients with MCI, the presence of any one vascular risk factor (hypertension, diabetes, smoking, cerebrovascular disease, hypercholesterolemia) was associated with an increased risk of conversion to dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/65\">",
"     65",
"    </a>",
"    ], but other studies have not found a significant association [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CSF biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the pathological processes of AD and other degenerative dementias are likely well underway before clinical symptoms manifest, biomarkers would seem to have potential utility in the early diagnosis of dementia. A number of smaller studies have examined the use of cerebrospinal fluid (CSF) markers for predicting conversion from MCI to dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/24,46,74\">",
"     24,46,74",
"    </a>",
"    ]. Associations have been suggested for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased levels of tau or tau protein phosphorylated at Thr 181 [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/17,29,75-83\">",
"       17,29,75-83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lower levels of amyloid beta 42 (A&szlig;42) peptide, a low ratio of A&szlig;42 to A&szlig;40 levels, and a low ratio of A&szlig;42 to tau levels [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/17,78-80,82,84-94\">",
"       17,78-80,82,84-94",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated levels and activity of beta-secretase [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/95\">",
"       95",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lower activity of neprilysin, an amyloid beta peptide degrading enzyme [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/96\">",
"       96",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher concentrations of soluble amyloid precursor proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/97\">",
"       97",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding of decreased A&szlig;42 is felt to reflect the accelerated deposition of amyloid protein in brain tissues and elevated tau and phosphorylated tau are considered to be an expression of neurofibrillary tangles. These pathologic changes and the low ratio of A&szlig;42 to tau levels are seen in AD. In a prospective cohort study, a low ratio of A&szlig;42 to tau levels was found in over 30 percent of healthy volunteers, greater than 50 percent of those with subjective reports of memory problems but cognitively normal, and nearly 70 and 80 percent for nonamnestic MCI (naMCI) and amnestic (aMCI) subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/91\">",
"     91",
"    </a>",
"    ]. This profile was associated with cognitive decline in both MCI groups and was predictive of future AD in patients with aMCI. One longitudinal study of patients with varying degrees of cognitive impairment (normal, MCI, AD) found that decreased levels of A&szlig;42 appeared to be an early marker of disease, appearing before clinical cognitive loss and neuroimaging abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study found that while MRI findings were superior to CSF markers in predicting future decline, predictive ability was further improved when the tests were combined [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The applicability of these findings to the general population is unclear, and these tests do not have an established role in the evaluation of patients with MCI in the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/99\">",
"     99",
"    </a>",
"    ]. In addition, a multicenter-study found that assays for CSF markers can vary, suggesting a need for better standardization of the assay [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/78\">",
"     78",
"    </a>",
"    ]. The absence of a clinical treatment imperative for MCI makes this relatively invasive test less appealing at this point in time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Plasma biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing investigations have focused on biomarkers in the serum or plasma that correlate with AD and other neurodegenerative dementias. An analysis of 120 signaling proteins in blood plasma found 18 that could be used to classify healthy controls from patients with AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. These were then studied in a series of 47 patients with MCI; these proteins identified 20 of 22 patients who developed clinical AD and none of the eight patients who developed nonAD dementia. Seven of 17 patients with stable MCI at follow-up had proteins suggestive of AD and continue to be followed for possible future progression to AD.",
"   </p>",
"   <p>",
"    Other investigations are focusing on soluble cell adhesion molecules in monocytes (eg, receptor for advanced glycation end products, RAGE) as potential biomarkers for AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. One meta-analysis found that a low ratio of A&szlig;42 to A&szlig;40 levels in plasma was associated with dementia risk (RR = 1.7) but that individual levels were not predictive of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic studies have shown that the earliest and most severe neurofibrillary manifestations of AD are found in the medial temporal lobe. Neuroimaging studies have focused attention on these and other areas to define structural abnormalities that may predict conversion from MCI to AD, as these appear to be more closely associated with MCI than other findings, such as white matter abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3031623\">",
"    <span class=\"h4\">",
"     MRI studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume loss or brain atrophy can be identified on magnetic resonance imaging (MRI) in cognitively normal patients who later develop AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. Temporal lobe atrophy may be an early specific marker for preclinical AD; similar patterns of temporal lobe atrophy are seen in patients with aMCI and AD, but are not seen in individuals with multiple domain naMCI, whose scans (at least in one study) are similar to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. While most studies use specialized techniques for volumetric measurements, visual assessment using a standardized rating scale seems to perform nearly as well [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. Efforts are underway to develop automated structural MRI techniques that allow patterns of atrophy to be quantitatively assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the degree and progression of medial temporal lobe atrophy on MRI are associated with conversion to dementia in patients with MCI as well as in people with normal baseline cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/24,25,28,52,70,79,80,83,99,112-114,116-133\">",
"     24,25,28,52,70,79,80,83,99,112-114,116-133",
"    </a>",
"    ]. These changes can be observed one to two years prior to cognitive decline and, at least in one study, are better predictors of future AD than CSF biomarkers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/80\">",
"     80",
"    </a>",
"    ]. Similarly, higher baseline apparent diffusion coefficient (ADC) values in the hippocampus on diffusion-weighted MRI (DWI) may predict conversion to dementia in patients with aMCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. Older age, APOE &epsilon;4, and poorer baseline cognition predicted progressive hippocampal atrophy in one study of patients with MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/136\">",
"     136",
"    </a>",
"    ]. Other longitudinal follow-up studies have found that thinning of the temporal and parietal cortex as determined by MRI morphometric analysis may be useful in predicting conversion from MCI to AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/130,137,138\">",
"     130,137,138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is overlap in the degree of atrophy for patients who do and do not progress to dementia, and the same is true for ADC values. While these findings are not clearly predictive of progression to dementia for individual patients, nonetheless, of the available markers, these MRI findings appear to be most proximate to conversion to dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/80,139-141\">",
"     80,139-141",
"    </a>",
"    ]. We note these findings as a marker of higher risk when we counsel patients.",
"   </p>",
"   <p>",
"    Similarly, while some investigations suggest that these MRI changes may be useful in combination with other risk factors in predicting risk of AD, such multivariate models require independent validation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/80,122\">",
"     80,122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have associated an increased extent of subcortical white matter hyperintensities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cortical infarction on MRI with MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/108,110,142-148\">",
"     108,110,142-148",
"    </a>",
"    ]. In one study of 170 individuals with MCI, this finding predicted the risk of vascular or mixed dementia over a median follow-up of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/149\">",
"     149",
"    </a>",
"    ]. More longitudinal studies are needed to assess whether an MRI finding of white matter hyperintensities or cerebral infarction represents a risk factor for further cognitive decline or progression to dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3031873\">",
"    <span class=\"h4\">",
"     PET, SPECT and fMRI studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of regional patterns of cortical hypometabolism using fluorodeoxyglucose (FDG) positron emission tomography (PET) may be useful for predicting conversion from MCI to AD, especially in the presence of the APOE &epsilon;4 allele [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/150-156\">",
"     150-156",
"    </a>",
"    ]. In another cohort, abnormal results on PET combined with impaired episodic memory identified a group 11.7 times more likely to convert to AD compared with individuals who tested normally on both measures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/93\">",
"     93",
"    </a>",
"    ]. However PET studies alone only marginally predicted cognitive decline in this patient group. This emphasizes the need to consider any diagnostic testing and prognostication in MCI to the context of the clinical encounter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/157\">",
"     157",
"    </a>",
"    ].The limited availability of PET in most medical centers is a current obstacle to widespread use.",
"   </p>",
"   <p>",
"    Amyloid PET tracers (eg, 11C-labeled Pittsburgh compound-B, PiB) show promise in the early diagnosis of AD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\", section on 'Neuroimaging'",
"    </a>",
"    .) Longitudinal follow-up studies of patients with MCI have shown that those with PiB retention have a higher rate of progression to dementia than those who do not [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/133,158-164\">",
"     133,158-164",
"    </a>",
"    ]. Higher PiB retention appeared in one study to correlate with a more rapid speed of conversion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/159\">",
"     159",
"    </a>",
"    ]. However, one study found that PiB retention was observed in 9 of 43 cognitively normal older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/165\">",
"     165",
"    </a>",
"    ], potentially indicative of future dementia. More studies that include longer follow-up times, more patients, and pathologic correlation are needed to define the role of amyloid PET imaging in patients with MCI.",
"   </p>",
"   <p>",
"    Single photon emission CT (SPECT) has also been studied as a test for AD and other forms of dementia. One study suggested that a subset of patients with aMCI who performed poorly on a test of visual recognition memory also exhibited patterns of temporomesial and temporoparietal hypoperfusion on SPECT, a pattern seen in early AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/166\">",
"     166",
"    </a>",
"    ]. However, there were no follow-up data on these patients assessing their risk of developing AD. Another study followed 105 patients with MCI; the 24 who developed AD within four years had reduced perfusion on baseline SPECT in specific brain areas compared with those who remained stable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/167\">",
"     167",
"    </a>",
"    ]. However, in the brain area most sensitive for early changes, the posterior cingulate, the average perfusion reduction was just 8 percent, which had limited ability to discriminate converters from nonconverters with a sensitivity and specificity of 79 and 67 percent.",
"   </p>",
"   <p>",
"    Functional MRI studies in individuals with MCI have found that greater memory task-related hippocampal activation predicts the rate and severity of subsequent cognitive decline [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/168,169\">",
"     168,169",
"    </a>",
"    ]. However, these and other described findings will require further confirmation in controlled studies to define their predictive value in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other potential risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found that impaired motor performance, in particular a parkinsonian gait and bradykinesia, was associated with conversion from MCI to AD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/171\">",
"     171",
"    </a>",
"    ]. In addition, individuals with MCI had levels of motor performance significantly inferior to those with normal cognition and superior to those with AD.",
"   </p>",
"   <p>",
"    In another small cohort study of 139 individuals with MCI, less than one drink of alcohol per day was associated with decreased progression to dementia compared with those who abstained (HR = 0.15) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/172\">",
"     172",
"    </a>",
"    ]. Higher amounts of alcohol intake were not associated with increased or decreased risk of dementia. Another longitudinal study found that daily drinking was associated with a higher risk of conversion of MCI to dementia (13 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/65\">",
"     65",
"    </a>",
"    ]. The role of alcohol in altering risk of MCI is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7320926\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;AD and other forms of dementia are associated with increased mortality. In one community health center-based cohort study, MCI was associated with an increased mortality hazard (HR=1.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/173\">",
"     173",
"    </a>",
"    ]. Other studies have also found that the presence and severity of MCI are associated with reduced survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/174\">",
"     174",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section covers studies that specifically evaluated treatments for mild cognitive impairment (MCI). Treatment of dementia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pharmacological",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no pharmacologic treatment that has a routine role in the management of patients with MCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Acetylcholinesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    in the treatment of MCI have not provided support for the use of acetylcholinesterase inhibitors in preventing progression of MCI to dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/16,175-181\">",
"     16,175-181",
"    </a>",
"    ]. A 2012 review and meta-analysis of available studies concluded that in patients with MCI there was little evidence that treatment with cholinesterase inhibitors affected progression to dementia or improved cognitive test scores and that there was significant evidence of an increased of treatment-associated adverse events, particularly gastrointestinal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/182\">",
"     182",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these results, acetylcholinesterase inhibitors are NOT routinely recommended for patients with MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/177,183\">",
"     177,183",
"    </a>",
"    ]. However, if memory difficulties are particularly troublesome to an individual patient, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    for symptomatic benefit may be warranted. Patients and families should be informed of the potential risks. The risks and benefits of acetylcholinesterase inhibitors in the treatment of dementia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=see_link\">",
"     \"Cholinesterase inhibitors in the treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for using antiinflammatory agents in patients with MCI is based on the evidence of an inflammatory component to the pathogenesis of AD, as well as some epidemiologic studies suggesting that nonsteroidal antiinflammatory drugs (NSAID) use in the general population is associated with a lower risk of AD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of dementia\", section on 'NSAID therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a large randomized controlled trial of 1457 patients with MCI, treatment with rofecoxib was not associated with a lower conversion rate to dementia at four years, nor did it affect secondary endpoint measures of cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/184\">",
"     184",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ginkgo biloba",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical trial evaluating the affects of Ginkgo biloba in preventing dementia in normal elderly and those with MCI found no benefit for treatment in preventing cognitive decline or the development of dementia among individuals with MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/185,186\">",
"     185,186",
"    </a>",
"    ]. In a clinical trial of 2854 patients aged 70 years and older with memory complaints (not necessarily meeting criteria for MCI), treatment with gingko biloba (120 mg twice per day) was not associated with a reduced incidence of dementia after five years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/187\">",
"     187",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57555165\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal nicotine was evaluated as a treatment for amnestic MCI in a placebo-controlled randomized study of 74 nonsmoking patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/188\">",
"     188",
"    </a>",
"    ]. After six months of treatment, transdermal nicotine was associated with improved cognitive measures but not in ratings of clinician-rated global impression of change (CGIC).",
"   </p>",
"   <p>",
"    Intranasal insulin was compared to placebo in 104 adults with amnestic MCI or mild to moderate dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/189\">",
"     189",
"    </a>",
"    ]. After four months, treatment for the combined group of aMCI and AD was associated with improved measures of memory, ADAS-cog score, and functional abilities, suggesting that further study of this therapy is warranted.",
"   </p>",
"   <p>",
"    In a clinical trial in nondemented adults, including 66 with MCI, 20 weeks of therapy with growth hormone-releasing hormone was associated with improved performance on cognitive tests compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/190\">",
"     190",
"    </a>",
"    ]. Longer term studies are needed to evaluate the safety and efficacy of this treatment approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vascular risk factor modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some feel that the association of MCI and vascular dementia has been underappreciated relative to AD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with MCI and AD have a higher than expected prevalence of atherosclerosis risk factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link&amp;anchor=H10#H10\">",
"       \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with MCI are likely to have cerebrovascular as well as AD pathology on postmortem examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link&amp;anchor=H11#H11\">",
"       \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebrovascular disease may play a prominent pathogenic role in dementia in many patients with AD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiology, clinical manifestations, and diagnosis of vascular dementia\", section on 'Mixed dementia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that atherosclerosis risk factors should be treated aggressively in patients with MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/183\">",
"     183",
"    </a>",
"    ]. There have been no randomized controlled clinical trials to support this; however, treatment of hypertension has been shown to reduce the incidence of dementia in the general population. There is less compelling evidence for the efficacy of antiplatelet therapy, statin therapy, and diabetes management in the treatment or prevention of dementia. While some observational studies suggest that treatment of vascular risk factors is associated with lower rates of conversion of MCI to dementia, these studies have substantial risk of bias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10104?source=see_link\">",
"     \"Treatment and prevention of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated homocysteine levels have been associated with risk of vascular disease, dementia, and decreased cognitive performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link&amp;anchor=H417059#H417059\">",
"     \"Risk factors for dementia\", section on 'Homocysteine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .) However, a systematic review of clinical trials concluded that supplementation with either vitamin B6, B12,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    folate has not been shown to improve cognition in individuals with MCI or normal cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/191\">",
"     191",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nonpharmacological interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of exercise programs ranging in duration from 6 to 12 months in two randomized trials of patients with MCI was associated with modest improvement in some cognitive measures in two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/192,193\">",
"     192,193",
"    </a>",
"    ], but not in another [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/194\">",
"     194",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cognitive interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various modalities of cognitive rehabilitation including memory training, the use of external memory cues, and organizational aids have been shown to improve function in healthy older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/195-197\">",
"     195-197",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of dementia\", section on 'Lifestyle and activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not clear if individuals with MCI may benefit from similar programs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/198\">",
"     198",
"    </a>",
"    ]. In one study, 52 individuals with MCI were randomly assigned to a cognitive rehabilitation program or a waitlist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/33/26138/abstract/199\">",
"     199",
"    </a>",
"    ]. Those receiving the intervention had improved performance on memory tasks compared to controls at two weeks and four months after the intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=see_link\">",
"       \"Patient information: Mild cognitive impairment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with MCI, particularly amnestic MCI, appear to be at risk for dementia. A conservative estimate of the risk is 10 percent per year. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Progression to dementia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuropsychological test measures, cerebrospinal fluid (CSF) biomarkers, and neuroimaging studies are being evaluated as predictive tools for assessing patients' risk for conversion to dementia. These lack standardization, and there is no clinical imperative for general use. Apolipoprotein E (APOE) epsilon 4 (&epsilon;4) genotype testing is also not recommended as a way to predict likelihood of progression. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No treatment has been shown to improve outcomes in patients with MCI. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on the available clinical trial data and lack of convincing benefit, we recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      routinely treating MCI with cholinesterase inhibitors (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For an individual patient with troublesome memory difficulties, a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      for symptomatic benefit may be warranted, although controlled study support for this recommendation is not available. Patients and families should be informed of the potential risks. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MCI and clinical or radiologic evidence of cerebrovascular pathology should be screened and treated for vascular risk factors. This approach has not been shown to alter conversion to dementia; however, there is convincing benefit for reduction of cerebrovascular and cardiovascular events. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Vascular risk factor modification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/1\">",
"      Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/2\">",
"      Manly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008; 63:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/3\">",
"      Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001; 56:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/4\">",
"      Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/5\">",
"      Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004; 63:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/6\">",
"      Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/7\">",
"      Palmer K, Wang HX, B&auml;ckman L, et al. Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry 2002; 159:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/8\">",
"      Wahlund LO, Pihlstrand E, J&ouml;nhagen ME. Mild cognitive impairment: experience from a memory clinic. Acta Neurol Scand Suppl 2003; 179:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/9\">",
"      Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology 2012; 79:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/10\">",
"      Lopez OL, Becker JT, Chang YF, et al. Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology 2012; 79:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/11\">",
"      Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/12\">",
"      Boyle PA, Wilson RS, Aggarwal NT, et al. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006; 67:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/13\">",
"      Busse A, Hensel A, G&uuml;hne U, et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/14\">",
"      Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 2008; 148:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/15\">",
"      Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology 2006; 67:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/16\">",
"      Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/17\">",
"      Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/18\">",
"      Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; 67:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/19\">",
"      Fischer P, Jungwirth S, Zehetmayer S, et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007; 68:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/20\">",
"      Lopez OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol 2007; 64:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/21\">",
"      Farias ST, Mungas D, Reed BR, et al. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 2009; 66:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/22\">",
"      Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry 2008; 79:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/23\">",
"      Stokholm J, Jakobsen O, Czarna JM, et al. Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer's disease. Neurocase 2005; 11:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/24\">",
"      Heister D, Brewer JB, Magda S, et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011; 77:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/25\">",
"      DeCarli C, Mungas D, Harvey D, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004; 63:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/26\">",
"      Kryscio RJ, Schmitt FA, Salazar JC, et al. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 2006; 66:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/27\">",
"      Tyas SL, Salazar JC, Snowdon DA, et al. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol 2007; 165:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/28\">",
"      Amieva H, Letenneur L, Dartigues JF, et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 2004; 18:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/29\">",
"      Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002; 59:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/30\">",
"      Peltz CB, Corrada MM, Berlau DJ, Kawas CH. Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments. Neurology 2011; 77:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/31\">",
"      Saxton J, Snitz BE, Lopez OL, et al. Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia. J Neurol Neurosurg Psychiatry 2009; 80:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/32\">",
"      Amieva H, Jacqmin-Gadda H, Orgogozo JM, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005; 128:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/33\">",
"      Fleisher AS, Sowell BB, Taylor C, et al. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2007; 68:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/34\">",
"      Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/35\">",
"      Sacuiu S, Sj&ouml;gren M, Johansson B, et al. Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. Neurology 2005; 65:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/36\">",
"      Laukka EJ, MacDonald SW, B&auml;ckman L. Contrasting cognitive trajectories of impending death and preclinical dementia in the very old. Neurology 2006; 66:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/37\">",
"      Nordlund A, Rolstad S, Klang O, et al. Two-year outcome of MCI subtypes and aetiologies in the G&ouml;teborg MCI study. J Neurol Neurosurg Psychiatry 2010; 81:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/38\">",
"      Ganguli M, Snitz BE, Saxton JA, et al. Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol 2011; 68:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/39\">",
"      Chang YL, Bondi MW, McEvoy LK, et al. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function. Neurology 2011; 76:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/40\">",
"      Tobiansky R, Blizard R, Livingston G, Mann A. The Gospel Oak Study stage IV: the clinical relevance of subjective memory impairment in older people. Psychol Med 1995; 25:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/41\">",
"      Geerlings MI, Jonker C, Bouter LM, et al. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999; 156:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/42\">",
"      van Norden AG, Fick WF, de Laat KF, et al. Subjective cognitive failures and hippocampal volume in elderly with white matter lesions. Neurology 2008; 71:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/43\">",
"      Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 2012; 79:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/44\">",
"      Barbeau E, Didic M, Tramoni E, et al. Evaluation of visual recognition memory in MCI patients. Neurology 2004; 62:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/45\">",
"      Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005; 64:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/46\">",
"      Riemenschneider M, Lautenschlager N, Wagenpfeil S, et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002; 59:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/47\">",
"      Chen P, Ratcliff G, Belle SH, et al. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology 2000; 55:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/48\">",
"      Aggarwal NT, Wilson RS, Beck TL, et al. Mild cognitive impairment in different functional domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/49\">",
"      P&eacute;r&egrave;s K, Chrysostome V, Fabrigoule C, et al. Restriction in complex activities of daily living in MCI: impact on outcome. Neurology 2006; 67:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/50\">",
"      Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 2007; 69:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/51\">",
"      Dickerson BC, Sperling RA, Hyman BT, et al. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 2007; 64:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/52\">",
"      Fleisher AS, Sun S, Taylor C, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 2008; 70:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/53\">",
"      Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006; 67:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/54\">",
"      Touchon J, Ritchie K. Prodromal cognitive disorder in Alzheimer's disease. Int J Geriatr Psychiatry 1999; 14:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/55\">",
"      Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol 2011; 68:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/56\">",
"      Ivnik RJ, Smith GE, Lucas JA, et al. Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. Neuropsychology 1999; 13:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/57\">",
"      Palmer K, Berger AK, Monastero R, et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 2007; 68:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/58\">",
"      Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 24:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/59\">",
"      Goveas JS, Espeland MA, Woods NF, et al. Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: the Women's Health Initiative Memory Study. J Am Geriatr Soc 2011; 59:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/60\">",
"      Caracciolo B, B&auml;ckman L, Monastero R, et al. The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: a cohort study of a community dwelling elderly population. J Neurol Neurosurg Psychiatry 2011; 82:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/61\">",
"      Ramakers IH, Visser PJ, Aalten P, et al. Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. Psychol Med 2010; 40:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/62\">",
"      Vicini Chilovi B, Conti M, Zanetti M, et al. Differential impact of apathy and depression in the development of dementia in mild cognitive impairment patients. Dement Geriatr Cogn Disord 2009; 27:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/63\">",
"      Panza F, Capurso C, D'Introno A, et al. Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging. Int J Geriatr Psychiatry 2008; 23:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/64\">",
"      Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/65\">",
"      Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011; 76:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/66\">",
"      Wang PN, Hong CJ, Lin KN, et al. APOE &epsilon;4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan. J Neurol Neurosurg Psychiatry 2011; 82:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/67\">",
"      Boyle PA, Buchman AS, Wilson RS, et al. The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 2010; 34:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/68\">",
"      Devanand DP, Pelton GH, Zamora D, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 2005; 62:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/69\">",
"      Aggarwal NT, Wilson RS, Beck TL, et al. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase 2005; 11:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/70\">",
"      Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000; 47:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/71\">",
"      Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, et al. Predictive value of APOE-&epsilon;4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/72\">",
"      Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/73\">",
"      Di Carlo A, Lamassa M, Baldereschi M, et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology 2007; 68:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/74\">",
"      Simonsen AH, McGuire J, Hansson O, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 2007; 64:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/75\">",
"      Maruyama M, Matsui T, Tanji H, et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol 2004; 61:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/76\">",
"      Buerger K, Ewers M, Andreasen N, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 2005; 65:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/77\">",
"      Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007; 69:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/78\">",
"      Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/79\">",
"      Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009; 73:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/80\">",
"      Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/81\">",
"      Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 2009; 80:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/82\">",
"      De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/83\">",
"      van Rossum IA, Vos SJ, Burns L, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 2012; 79:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/84\">",
"      Skoog I, Davidsson P, Aevarsson O, et al. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003; 15:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/85\">",
"      Moonis M, Swearer JM, Dayaw MP, et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 2005; 65:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/86\">",
"      Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/87\">",
"      Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007; 69:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/88\">",
"      Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009; 65:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/89\">",
"      Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/90\">",
"      Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009; 66:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/91\">",
"      Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/92\">",
"      Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/93\">",
"      Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/94\">",
"      Sepp&auml;l&auml; TT, Herukka SK, H&auml;nninen T, et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 2010; 81:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/95\">",
"      Zhong Z, Ewers M, Teipel S, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007; 64:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/96\">",
"      Maruyama M, Higuchi M, Takaki Y, et al. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol 2005; 57:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/97\">",
"      Perneczky R, Tsolakidou A, Arnold A, et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 2011; 77:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/98\">",
"      Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011; 68:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/99\">",
"      Vemuri P, Wiste HJ, Weigand SD, et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 2010; 75:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/100\">",
"      Britschgi M, Wyss-Coray T. Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol 2009; 66:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/101\">",
"      Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/102\">",
"      O'Bryant SE, Xiao G, Barber R, et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010; 67:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/103\">",
"      Ghidoni R, Benussi L, Glionna M, et al. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 2008; 115:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/104\">",
"      Hochstrasser T, Weiss E, Marksteiner J, Humpel C. Soluble cell adhesion molecules in monocytes of Alzheimer's disease and mild cognitive impairment. Exp Gerontol 2010; 45:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/105\">",
"      Koyama A, Okereke OI, Yang T, et al. Plasma amyloid-&beta; as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 2012; 69:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/106\">",
"      van de Pol LA, Korf ES, van der Flier WM, et al. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol 2007; 64:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/107\">",
"      Fox NC, Crum WR, Scahill RI, et al. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/108\">",
"      Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008; 65:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/109\">",
"      Becker JT, Davis SW, Hayashi KM, et al. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Arch Neurol 2006; 63:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/110\">",
"      Stewart R, Dufouil C, Godin O, et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology 2008; 70:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/111\">",
"      Zimmerman ME, Pan JW, Hetherington HP, et al. Hippocampal neurochemistry, neuromorphometry, and verbal memory in nondemented older adults. Neurology 2008; 70:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/112\">",
"      Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004; 63:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/113\">",
"      Geroldi C, Rossi R, Calvagna C, et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry 2006; 77:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/114\">",
"      DeCarli C, Frisoni GB, Clark CM, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007; 64:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/115\">",
"      Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/116\">",
"      Stoub TR, Bulgakova M, Leurgans S, et al. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005; 64:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/117\">",
"      Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 2005; 65:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/118\">",
"      Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/119\">",
"      Bell-McGinty S, Lopez OL, Meltzer CC, et al. Differential cortical atrophy in subgroups of mild cognitive impairment. Arch Neurol 2005; 62:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/120\">",
"      Erten-Lyons D, Howieson D, Moore MM, et al. Brain volume loss in MCI predicts dementia. Neurology 2006; 66:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/121\">",
"      Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol 2006; 63:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/122\">",
"      Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007; 68:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/123\">",
"      Whitwell JL, Shiung MM, Przybelski SA, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008; 70:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/124\">",
"      Jack CR Jr, Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008; 70:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/125\">",
"      Desikan RS, Fischl B, Cabral HJ, et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology 2008; 71:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/126\">",
"      Duara R, Loewenstein DA, Potter E, et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 2008; 71:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/127\">",
"      McEvoy LK, Fennema-Notestine C, Roddey JC, et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009; 251:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/128\">",
"      Henneman WJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009; 72:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/129\">",
"      Davatzikos C, Xu F, An Y, et al. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain 2009; 132:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/130\">",
"      Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009; 132:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/131\">",
"      den Heijer T, van der Lijn F, Koudstaal PJ, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010; 133:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/132\">",
"      Verdelho A, Madureira S, Moleiro C, et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010; 75:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/133\">",
"      Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/134\">",
"      Kantarci K, Petersen RC, Boeve BF, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2005; 64:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/135\">",
"      Ray KM, Wang H, Chu Y, et al. Mild cognitive impairment: apparent diffusion coefficient in regional gray matter and white matter structures. Radiology 2006; 241:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/136\">",
"      van de Pol LA, van der Flier WM, Korf ES, et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 2007; 69:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/137\">",
"      Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009; 72:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/138\">",
"      Querbes O, Aubry F, Pariente J, et al. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain 2009; 132:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/139\">",
"      Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/140\">",
"      Holland D, Brewer JB, Hagler DJ, et al. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106:20954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/141\">",
"      Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/142\">",
"      DeCarli C, Miller BL, Swan GE, et al. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001; 58:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/143\">",
"      Bombois S, Debette S, Delbeuck X, et al. Prevalence of subcortical vascular lesions and association with executive function in mild cognitive impairment subtypes. Stroke 2007; 38:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/144\">",
"      Debette S, Bombois S, Bruandet A, et al. Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke 2007; 38:2924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/145\">",
"      Kantarci K, Weigand SD, Przybelski SA, et al. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 2009; 72:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/146\">",
"      Luchsinger JA, Brickman AM, Reitz C, et al. Subclinical cerebrovascular disease in mild cognitive impairment. Neurology 2009; 73:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/147\">",
"      Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010; 41:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/148\">",
"      Silbert LC, Dodge HH, Perkins LG, et al. Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology 2012; 79:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/149\">",
"      Bombois S, Debette S, Bruandet A, et al. Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. Stroke 2008; 39:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/150\">",
"      Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004; 63:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/151\">",
"      Ch&eacute;telat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/152\">",
"      Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005; 62:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/153\">",
"      Jagust W, Gitcho A, Sun F, et al. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 2006; 59:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/154\">",
"      Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/155\">",
"      Caselli RJ, Chen K, Lee W, et al. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008; 65:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/156\">",
"      Fouquet M, Desgranges B, Landeau B, et al. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain 2009; 132:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/157\">",
"      Petersen RC. Does the source of subjects matter?: absolutely! Neurology 2010; 74:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/158\">",
"      Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/159\">",
"      Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/160\">",
"      Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/161\">",
"      Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010; 74:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/162\">",
"      Small GW, Siddarth P, Kepe V, et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012; 69:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/163\">",
"      Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-&beta; assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012; 79:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/164\">",
"      Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/165\">",
"      Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/166\">",
"      Guedj E, Barbeau EJ, Didic M, et al. Identification of subgroups in amnestic mild cognitive impairment. Neurology 2006; 67:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/167\">",
"      Johnson KA, Moran EK, Becker JA, et al. Single photon emission computed tomography perfusion differences in mild cognitive impairment. J Neurol Neurosurg Psychiatry 2007; 78:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/168\">",
"      Miller SL, Fenstermacher E, Bates J, et al. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry 2008; 79:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/169\">",
"      O'Brien JL, O'Keefe KM, LaViolette PS, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010; 74:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/170\">",
"      Petrella JR, Sheldon FC, Prince SE, et al. Default mode network connectivity in stable vs progressive mild cognitive impairment. Neurology 2011; 76:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/171\">",
"      Aggarwal NT, Wilson RS, Beck TL, et al. Motor dysfunction in mild cognitive impairment and the risk of incident Alzheimer disease. Arch Neurol 2006; 63:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/172\">",
"      Solfrizzi V, D'Introno A, Colacicco AM, et al. Alcohol consumption, mild cognitive impairment, and progression to dementia. Neurology 2007; 68:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/173\">",
"      Sachs GA, Carter R, Holtz LR, et al. Cognitive impairment: an independent predictor of excess mortality: a cohort study. Ann Intern Med 2011; 155:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/174\">",
"      Wilson RS, Aggarwal NT, Barnes LL, et al. Biracial population study of mortality in mild cognitive impairment and Alzheimer disease. Arch Neurol 2009; 66:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/175\">",
"      Lu PH, Edland SD, Teng E, et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 2009; 72:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/176\">",
"      Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/177\">",
"      Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006; :CD006104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/178\">",
"      Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009; 72:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/179\">",
"      Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/180\">",
"      Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment. BMJ 2005; 330:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/181\">",
"      Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/182\">",
"      Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012; 9:CD009132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/183\">",
"      Chertkow H, Massoud F, Nasreddine Z, et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ 2008; 178:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/184\">",
"      Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/185\">",
"      DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/186\">",
"      Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009; 302:2663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/187\">",
"      Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/188\">",
"      Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 2012; 78:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/189\">",
"      Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/190\">",
"      Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone&ndash;releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 2012; 69:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/191\">",
"      Balk EM, Raman G, Tatsioni A, et al. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med 2007; 167:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/192\">",
"      Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008; 300:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/193\">",
"      Nagamatsu LS, Handy TC, Hsu CL, et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Arch Intern Med 2012; 172:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/194\">",
"      van Uffelen JG, Chinapaw MJ, van Mechelen W, Hopman-Rock M. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. Br J Sports Med 2008; 42:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/195\">",
"      Verhaeghen P, Marcoen A, Goossens L. Improving memory performance in the aged through mnemonic training: a meta-analytic study. Psychol Aging 1992; 7:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/196\">",
"      Stuss DT, Robertson IH, Craik FI, et al. Cognitive rehabilitation in the elderly: a randomized trial to evaluate a new protocol. J Int Neuropsychol Soc 2007; 13:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/197\">",
"      Troyer, AK. Improving memory, knowledge, satisfaction, and functioning via an education and intervention program for older adults. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2001; 8:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/198\">",
"      Jean L, Bergeron ME, Thivierge S, Simard M. Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry 2010; 18:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/33/26138/abstract/199\">",
"      Kinsella GJ, Mullaly E, Rand E, et al. Early intervention for mild cognitive impairment: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2009; 80:730.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5091 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5CB361C86E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26138=[""].join("\n");
var outline_f25_33_26138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGRESSION TO DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predictors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Neuropsychological testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Psychological features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - ApoE epsilon 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7911102\">",
"      - Vascular risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CSF biomarkers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Plasma biomarkers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3031623\">",
"      MRI studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3031873\">",
"      PET, SPECT and fMRI studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other potential risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7320926\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pharmacological",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Acetylcholinesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57555165\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vascular risk factor modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nonpharmacological interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cognitive interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5091\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5091|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/0/2\" title=\"table 1\">",
"      Clinical dementia rating",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=related_link\">",
"      Cholinesterase inhibitors in the treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32089?source=related_link\">",
"      Genetics of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=related_link\">",
"      Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=related_link\">",
"      Patient information: Mild cognitive impairment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10104?source=related_link\">",
"      Treatment and prevention of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_33_26139="Causes of hirsutism in women";
var content_f25_33_26139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hirsutism in women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic hirsutism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonclassic 21-hydroxylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Danazol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital adrenal hyperplasia (most often 21-hydroxylase deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthecosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ovarian tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sertoli-Leydig cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Granulosa-theca cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hilus-cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe insulin resistance syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperprolactinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cushing's syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26139=[""].join("\n");
var outline_f25_33_26139=null;
var title_f25_33_26140="Thrombolytic regimens STEMI";
var content_f25_33_26140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preferred thrombolytic regimens for acute ST elevation myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended IV regimen*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages and limitations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Alteplase (accelerated regimen)",
"       </td>",
"       <td>",
"        15 mg bolus",
"       </td>",
"       <td rowspan=\"3\">",
"        Better outcomes than streptokinase in GUSTO-1 (30-day mortality 6.3 versus 7.3 percent); costlier than streptokinase; more difficult to administer because of short half-life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         then",
"        </strong>",
"        0.75 mg/kg (maximum 50 mg) over 30 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         then",
"        </strong>",
"        0.5 mg/kg (maximum 35 mg) over the next 60 minutes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Tenecteplase",
"       </td>",
"       <td>",
"        Single bolus over five to ten seconds based upon body weight:",
"       </td>",
"       <td rowspan=\"6\">",
"        As effective as alteplase in ASSENT-2 with less noncerebral bleeding and need for transfusion; easier to administer (single bolus due to longer half-life) both in and out of hospital; these advantages make tenecteplase the drug of choice in many US hospitals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;60 kg: 30 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        60 to 69 kg: 35 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        70 to 79 kg: 40 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        80 to 89 kg: 45 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;90 kg: 50 mg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Reteplase",
"       </td>",
"       <td>",
"        10 units over two minutes then repeat 10 unit bolus at 30 minutes",
"       </td>",
"       <td>",
"        Similar outcomes as alteplase but easier to administer",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Streptokinase",
"       </td>",
"       <td>",
"        1.5 million units over 30 to 60 minutes",
"       </td>",
"       <td>",
"        Generally a much less costly option than other fibrinolytics but outcomes are inferior. Neutralizing antibodies develop, which can diminish efficacy of subsequent use. Elevated risk of hypersensitivity reaction with repeated doses. Used extensively outside North America due to lower cost. (Not available in US or CAN).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All patients are also given non enteric-coated aspirin 162 to 325 mg and, with alteplase, reteplase, and tenecteplase, unfractionated heparin as a 60 units/kg bolus (maximum 4000 units) followed by an intravenous infusion of 12 units/kg per hour (maximum 1000 units per hour) adjusted to target aPTT of 50 to 70 seconds. Heparin has not been definitively shown to improve outcomes with non-fibrin-specific agents such as streptokinase. However, heparin is recommended with streptokinase in patients who are at high risk for systemic thromboembolism (large or anterior myocardial infarction, atrial fibrillation, previous embolus, or known left ventricular thrombus).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26140=[""].join("\n");
var outline_f25_33_26140=null;
var title_f25_33_26141="SIDS support groups PI";
var content_f25_33_26141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sudden infant death syndrome support groups",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Association of SIDS and Infant Mortality Programs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        112 E. Allegan, suite 500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lansing, MI 48933",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-800-930-7437",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:info@asip1.org\">",
"         <span style=\"color: #3966bf;\">",
"          info@asip1.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.asip1.org/\">",
"         <span style=\"color: #3966bf;\">",
"          www.asip1.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National SUID/SIDS Resource Center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2115 Wisconsin Avenue, NW",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suite 601",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Washington DC, 20007",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-866-866-7437 or 1-202-687-7466",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:info@sidscenter.org\">",
"         <span style=\"color: #3966bf;\">",
"          info@sidscenter.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.sidscenter.org/\">",
"         <span style=\"color: #3966bf;\">",
"          www.sidscenter.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        First Candle/SIDS Alliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (a national network of SIDS support groups)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1314 Bedford Avenue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suite 210 Baltimore, MD 21208",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-800-221-7437 or 1-410-653-8226",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:info@firstcandle.org\">",
"         <span style=\"color: #0000ff;\">",
"          info@firstcandle.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.firstcandle.org/\">",
"         <span style=\"color: #3966bf;\">",
"          www.firstcandle.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Foundation for the Study of Infant Deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artillery House",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-19 Artillery Row",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        London, SWIP IRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        020 7233 2090",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:fsid@fsid.org.uk\">",
"         <span style=\"color: #3966bf;\">",
"          fsid@fsid.org.uk",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.fsid.org.uk/\">",
"         <span style=\"color: #3966bf;\">",
"          www.fsid.org.uk",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Canadian Foundation for the Study of Infant Deaths (CFSID)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        586 Eglinton Avenue East",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suite 308",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toronto, Ontario, Canada M4P 1P2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-800-363-7437 (toll-free) or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-416-488-3260 or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-416-488-3864 (fax)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:sidsinfo@sidscanada.org\">",
"         <span style=\"color: #3966bf;\">",
"          sidsinfo@sidscanada.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.sidscanada.org/\">",
"         <span style=\"color: #3966bf;\">",
"          www.sidscanada.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National SIDS Council of Australia, Ltd.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suite 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        98 Morang Road",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hawthorn, VIC 3122, Australia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        03 9819 4595 or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        03 9818 4596 (fax)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:national@sidsandkids.org\">",
"         <span style=\"color: #3966bf;\">",
"          national@sidsandkids.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.sidsandkids.org/\">",
"         <span style=\"color: #3966bf;\">",
"          www.sidsandkids.org",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        SIDS Family Association Japan (SIDSFAJ)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        email:",
"        <a href=\"mailto:englishcontact@sids.gr.jp\">",
"         <span style=\"color: #3966bf;\">",
"          englishcontact@sids.gr.jp",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        website:",
"        <a href=\"file://www.sids.gr.jp/\">",
"         <span style=\"color: #3966bf;\">",
"          www.sids.gr.jp",
"         </span>",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: the National Institute of Child Health &amp; Human Development Fact Sheet: Sudden infant death syndrome (www.nichd.nih.gov/publications/pubs/sidsfact.htm).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26141=[""].join("\n");
var outline_f25_33_26141=null;
var title_f25_33_26142="OK sign to assess median nerve";
var content_f25_33_26142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    OK sign to assess median nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The OK sign evaluates the anterior interosseous branch of the median nerve by testing the strength of the flexor pollicis longus and flexor digitorum profundus. The patient is asked to make the OK sign and then maintain&nbsp;it against resistance (pictured above).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26142=[""].join("\n");
var outline_f25_33_26142=null;
var title_f25_33_26143="Nasal pillows";
var content_f25_33_26143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal pillows",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Mirage Swift mask (ResMed, Inc. San Diego, CA) has nasal \"pillows\" that fit into nares. This mask design removes the sealing surface from the nose and mouth and minimizes hardware over the eyes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; ResMed 2010. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_33_26143=[""].join("\n");
var outline_f25_33_26143=null;
